[go: up one dir, main page]

DE69233528D1 - Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen - Google Patents

Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen

Info

Publication number
DE69233528D1
DE69233528D1 DE69233528T DE69233528T DE69233528D1 DE 69233528 D1 DE69233528 D1 DE 69233528D1 DE 69233528 T DE69233528 T DE 69233528T DE 69233528 T DE69233528 T DE 69233528T DE 69233528 D1 DE69233528 D1 DE 69233528D1
Authority
DE
Germany
Prior art keywords
heterodimer
preparation
binding proteins
sfv
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233528T
Other languages
English (en)
Other versions
DE69233528T2 (de
Inventor
Marc D Whitlow
James F Wood
Karl Hardman
Robert E Bird
David Filpula
Michele Rollence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25169441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233528(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enzon Inc filed Critical Enzon Inc
Publication of DE69233528D1 publication Critical patent/DE69233528D1/de
Application granted granted Critical
Publication of DE69233528T2 publication Critical patent/DE69233528T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69233528T 1991-11-25 1992-11-20 Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen Expired - Lifetime DE69233528T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79693691A 1991-11-25 1991-11-25
US796936 1991-11-25

Publications (2)

Publication Number Publication Date
DE69233528D1 true DE69233528D1 (de) 2005-07-14
DE69233528T2 DE69233528T2 (de) 2006-03-16

Family

ID=25169441

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69232137T Expired - Fee Related DE69232137T2 (de) 1991-11-25 1992-11-20 Multivalente antigen-bindende proteine
DE69233528T Expired - Lifetime DE69233528T2 (de) 1991-11-25 1992-11-20 Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69232137T Expired - Fee Related DE69232137T2 (de) 1991-11-25 1992-11-20 Multivalente antigen-bindende proteine

Country Status (10)

Country Link
US (1) US20060063715A1 (de)
EP (2) EP1136556B1 (de)
JP (1) JPH07501451A (de)
AT (2) ATE297465T1 (de)
AU (1) AU3178993A (de)
CA (1) CA2122732C (de)
DE (2) DE69232137T2 (de)
DK (2) DK0617706T3 (de)
ES (2) ES2165851T3 (de)
WO (1) WO1993011161A1 (de)

Families Citing this family (1630)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
EP1550729B1 (de) * 1992-09-25 2009-05-27 Avipep Pty Limited Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
DK0676965T3 (da) * 1992-11-16 2007-11-19 Centocor Inc Fremgangsmåde til at reducere immunogeniciteten af variable regioner på antistoffer
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
ES2156149T3 (es) * 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
SG55079A1 (en) * 1992-12-11 1998-12-21 Dow Chemical Co Multivalent single chain antibodies
DE69414870T2 (de) 1993-09-22 1999-05-12 Medical Research Council, London Antikoerper mit geaenderter zielrichtung
GB9412166D0 (en) * 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
BR9606706A (pt) * 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
US6239259B1 (en) 1996-04-04 2001-05-29 Unilever Patent Holdings B.V. Multivalent and multispecific antigen-binding protein
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
IT1286663B1 (it) * 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
DK0971959T3 (da) 1997-04-07 2006-05-15 Genentech Inc Humaniserede antistoffer og fremgangsmåder til dannelse af humaniserede antistoffer
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
GB9710154D0 (en) * 1997-05-16 1997-07-09 Medical Res Council Detection of retroviruses
ATE361930T1 (de) 1997-06-13 2007-06-15 Genentech Inc Proteinreinigung mittels chromatographie und darauffolgende filtration auf beladener schicht
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6670453B2 (en) 1997-10-27 2003-12-30 Unilever Patent Holdings B.V. Multivalent antigen-binding proteins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
ATE364049T1 (de) 1997-11-21 2007-06-15 Genentech Inc Mit a33 verwandte antigene und deren pharmazeutische verwendungen
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
EP1947119A3 (de) 1997-12-12 2012-12-19 Genentech, Inc. Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
EP2189791A3 (de) 1998-02-04 2011-03-09 Life Technologies Corporation Mikroarrays und Verwendungen dafür
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP1941905A1 (de) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1978029A3 (de) 1999-06-15 2008-10-15 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
BR122014028365B8 (pt) 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
JP2003522324A (ja) * 1999-08-11 2003-07-22 ユニリーバー・ナームローゼ・ベンノートシヤープ 内部標準イムノアッセイおよび試験装置
HK1048260B (zh) 1999-08-27 2009-03-13 杰南技术公司 用於抗erbb2抗体治疗的制剂
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
MXPA02003897A (es) 1999-10-20 2002-12-13 Genentech Inc Modulacion de la diferenciacion de celulas t para el tratamiento de enfermedades mediadas por las celulas t auxiliares.
CA2491258A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897947B1 (de) 1999-12-23 2012-01-18 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
IL150676A0 (en) 2000-01-13 2003-02-12 Genentech Inc NOVEL STRa6 POLYPEPTIDES
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
DE10021678A1 (de) * 2000-05-05 2002-04-18 Stefan Duebel Antikörperkonstrukte mit variablen Regionen
AU2001268363B2 (en) 2000-06-20 2006-08-17 Biogen Idec Inc. Treatment of B cell associated diseases
EP2075253A1 (de) 2000-06-23 2009-07-01 Genentech, Inc. Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
EP2042597B1 (de) 2000-06-23 2014-05-07 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US7534429B2 (en) 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
PT1392359E (pt) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
GB0111628D0 (en) 2001-05-11 2001-07-04 Scancell Ltd Binding member
CN1684708A (zh) 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633595A1 (en) 2001-06-20 2003-01-03 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
KR100968664B1 (ko) 2001-08-27 2010-07-06 제넨테크, 인크. 항체 발현 및 조립을 위한 시스템
PL368972A1 (en) 2001-08-29 2005-04-04 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
JP4381140B2 (ja) 2001-10-12 2009-12-09 シェーリング コーポレイション 免疫応答を調節するための二重特異性抗体の使用
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1456386B1 (de) * 2001-11-16 2009-01-14 Biogen Idec Inc. Polycistronische expression von antikörpern in cho zellen
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
WO2003057881A1 (fr) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
CA2471431A1 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2472937C (en) 2002-01-11 2014-06-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
ATE469240T1 (de) 2002-04-12 2010-06-15 Colorado School Of Mines Verfahren zum nachweis geringer konzentrationen eines zielbakteriums unter verwendung von phagen zur infizierung von zielbakterienzellen
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
AU2003247806B2 (en) 2002-07-08 2009-11-12 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
CN102295703A (zh) 2002-07-15 2011-12-28 健泰科生物技术公司 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
WO2004015425A1 (en) 2002-08-07 2004-02-19 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
EP1578373A4 (de) 2002-09-11 2007-10-24 Genentech Inc Neue zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
CA2498008C (en) 2002-09-11 2014-02-04 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
SI1543038T2 (sl) 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
SG146441A1 (en) 2002-10-22 2008-10-30 Eisai R&D Man Co Ltd Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
CA2503330A1 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006516094A (ja) 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド ナチュラルキラー細胞関連疾患の治療のための組成物と方法
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
CN1787837A (zh) 2002-11-15 2006-06-14 希龙公司 防止和治疗癌转移以及与癌转移相关的骨质损失的方法
WO2004048552A2 (en) 2002-11-21 2004-06-10 Celltech R & D, Inc. Modulating immune responses
EP1572116A4 (de) 2002-11-26 2007-12-12 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
EP1592387A4 (de) 2003-01-24 2009-05-06 Elan Pharm Inc Zusammensetzung für und behandlung von entmyelinierenden erkrankungen und paralyse durch verabreichung von remyelinierenden mitteln
WO2004070016A2 (en) 2003-02-03 2004-08-19 Fraunhofer Usa Inc. System for expression of genes in plants
NZ541480A (en) 2003-03-12 2008-03-28 Genentech Inc Use of Bv8 and/or EG-VEGF to promote hematopoiesis
DE602004029015D1 (de) 2003-04-04 2010-10-21 Genentech Inc Hochkonzentrierter antikörper und proteinformulierungen
KR20110044809A (ko) 2003-04-09 2011-04-29 제넨테크, 인크. Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는 환자에서의 자가면역 질환의 치료법
NZ543960A (en) 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
EP1664322B1 (de) 2003-05-22 2013-07-10 Fraunhofer USA, Inc. Rekombinantes trägermolekül zur expression, zuführung und reinigung von zielpolypeptiden
WO2004111192A2 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
RS20050885A (sr) 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
DE602004028249D1 (de) 2003-06-18 2010-09-02 Chugai Pharmaceutical Co Ltd Fucosetransporter
JP5340537B2 (ja) 2003-07-08 2013-11-13 ジェネンテック， インコーポレイテッド Ｉｌ−１７異種ポリペプチドとその治療上の用途
EP1641829A1 (de) * 2003-07-09 2006-04-05 Schering AG Emitter-bindende peptide die eine ver nderung der spektralen emissionseigenschaften des emitters bewirken
DE10331054A1 (de) * 2003-07-09 2005-02-03 Schering Ag Emitter-bindende Peptide die eine Veränderung der spektralen Emissionseigenschaften des Emitters bewirken
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
JPWO2005035754A1 (ja) 2003-10-14 2006-12-21 中外製薬株式会社 機能蛋白質を代替する二種特異性抗体
US7304139B2 (en) 2003-10-28 2007-12-04 University Of Florida Research Foundation, Inc. Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
BRPI0416243A (pt) 2003-11-05 2007-01-09 Palingen Inc método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
EP1725249B1 (de) 2003-11-06 2014-01-08 Seattle Genetics, Inc. Monomethylvalinverbindungen, die dazu in der lage sind, liganden zu konjugieren
PE20090046A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
EP1691836B1 (de) 2003-11-13 2012-02-22 Sutter West Bay Hospitals Anti-pecam-therapie zur unterdrückung von metastasen
ATE453405T1 (de) 2003-11-17 2010-01-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
JPWO2005056605A1 (ja) 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
PL1704166T3 (pl) 2004-01-07 2015-10-30 Novartis Vaccines & Diagnostics Inc Przeciwciała monoklonalne swoiste względem M-CSF i ich zastosowania
EP2168986A3 (de) 2004-02-19 2010-07-28 Genentech, Inc. Antikörper mit korrigiertem CDR
KR100924044B1 (ko) 2004-03-31 2009-10-27 캐논 가부시끼가이샤 표적 물질 포착 구조체
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
JP2007538258A (ja) 2004-05-15 2007-12-27 ジェネンテック・インコーポレーテッド 標的分子に結合親和性を有する分子を検出するためのクロススクリーニングシステムと方法
PL1753871T3 (pl) 2004-05-28 2016-01-29 Agensys Inc Przeciwciała i powiązane cząsteczki, które wiążą się z antygenem komórek macierzystych prostaty (PSCA)
RU2404810C9 (ru) 2004-06-01 2015-06-20 Дженентек, Инк. Конъюгаты антитело-лекарственное средство и способы
RU2384345C2 (ru) 2004-06-04 2010-03-20 Дженентек, Инк. Способ лечения рассеянного склероза
US7604947B2 (en) 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
CA2572384A1 (en) 2004-07-01 2006-02-02 University Of Southern California Genetic markers for predicting disease and treatment outcome
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
MX2007000784A (es) 2004-07-20 2007-04-09 Genentech Inc Inhibidores de proteina 4 tipo angiopoietina, combinaciones y su uso.
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
WO2006009241A1 (ja) 2004-07-22 2006-01-26 Eisai Co., Ltd. Lrp4/Corinドーパミン産生ニューロン前駆細胞マーカー
BRPI0513826A2 (pt) 2004-07-26 2010-06-22 Dow Global Technologies Inc processo para expressão de proteìna melhorada através de engenharia de cepa
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
ZA200701614B (en) 2004-08-06 2008-10-29 Genentech Inc Assays and methods using biomarkers
AU2005271249A1 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
SI1791565T1 (sl) 2004-09-23 2016-08-31 Genentech, Inc. Cisteinsko konstruirana protitelesa in konjugati
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
SG165344A1 (en) 2004-10-05 2010-10-28 Genentech Inc Method for treating vasculitis
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2311433A3 (de) 2004-10-21 2011-08-10 Genentech, Inc. Verfahren zur Behandlung von intraokularen neovaskulären Erkrankungen
KR20080007425A (ko) 2004-11-05 2008-01-21 팔링겐, 인코포레이티드 항체 유도된 세포막 손상
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
DK1841793T3 (da) 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
CA2593328C (en) 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
TR201901841T4 (tr) 2005-01-21 2019-03-21 Genentech Inc Her antikorlarının sabit dozlaması.
US20060233791A1 (en) 2005-02-15 2006-10-19 Duke University Anti-CD19 antibodies and uses in oncology
PL1850874T3 (pl) 2005-02-23 2014-03-31 Genentech Inc Wydłużanie czasu do progresji choroby lub przeżycia u chorych na raka jajnika stosujących pertuzumab
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
NZ562453A (en) 2005-03-31 2010-04-30 Agensys Inc Antibodies and related molecules that bind to 161P2F10B proteins
US8092990B2 (en) 2005-03-31 2012-01-10 Colorado School Of Mines Apparatus and method for detecting microscopic organisms using bacteriophage
CA2603264C (en) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
JP5341505B2 (ja) 2005-04-09 2013-11-13 フージョン アンティボディーズ リミテッド 抗体及びその使用
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP2377884A1 (de) 2005-05-10 2011-10-19 Neoloch Aps Neuritogene peptide
SI1879573T1 (sl) 2005-05-10 2013-04-30 Incyte Corporation Experimental Station Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te
PT3415535T (pt) 2005-05-20 2021-02-02 Ablynx Nv Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
NZ563341A (en) 2005-06-06 2009-10-30 Genentech Inc Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
CN102775493B (zh) 2005-06-21 2015-10-28 爱克索马美国有限责任公司 IL-1β结合抗体及其片段
EP1917020B1 (de) 2005-07-07 2016-05-25 Seattle Genetics, Inc. Monomethylvalin-verbindungen mit phenylalanin-seitenketten-modifikationen am c-terminus
AU2006268227A1 (en) 2005-07-08 2007-01-18 Xencor, Inc Optimized anti-Ep-CAM antibodies
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
SG10201403526YA (en) * 2005-07-25 2014-10-30 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
EP1913027B1 (de) 2005-07-28 2015-03-04 Novartis AG M-csf-spezifische monoklonale antikörper und anwendungen davon
ES2660026T3 (es) 2005-07-29 2018-03-20 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7452978B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
BRPI0614475B8 (pt) 2005-08-03 2021-05-25 Fraunhofer Usa Inc polipeptídeo, anticorpo, ácido nucleico, vetores, célula hospedeira, composição e processos de produção de anticorpo
DE602006019262D1 (de) 2005-08-11 2011-02-10 Siemens Healthcare Diagnostics QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
CA2619577A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2619759A1 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for galnac-t14 expression in cells/tissues
HRP20170444T1 (hr) 2005-08-31 2017-05-19 Merck Sharp & Dohme Corp. Projektirana anti-il-23 antitijela
EP1934867A2 (de) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
SI1933869T1 (sl) 2005-09-01 2010-02-26 Schering Corp Uporaba IL-23 in IL-17 antagonistov za zdravljenje avtoimunske očesne vnetne bolezni
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
EP1942922A4 (de) 2005-11-04 2011-03-30 Genentech Inc Verwendung von hemmern des komplementpfads zur behandlung von augenerkrankungen
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP2392588A3 (de) 2005-11-11 2012-03-07 Vertex Pharmaceuticals Incorporated Hepatitis-C-Virusvarianten
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
HRP20150691T1 (hr) 2005-11-18 2015-11-06 Glenmark Pharmaceuticals S.A. Anti-alfa2 integrin protutijela i njihova uporaba
EP1962584A2 (de) 2005-11-21 2008-09-03 Genentech, Inc. Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
PL1963369T3 (pl) 2005-11-28 2013-10-31 Zymogenetics Inc Antagoniści IL-21
CA2631327C (en) 2005-12-02 2015-10-13 Genentech, Inc. Her2 binding polypeptides and uses thereof
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20090246208A1 (en) 2006-01-05 2009-10-01 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
KR101589391B1 (ko) 2006-01-05 2016-01-29 제넨테크, 인크. 항-ｅｐｈｂ４ 항체 및 그의 사용 방법
US7514077B2 (en) 2006-01-10 2009-04-07 Zymogenetics, Inc. Methods of antagonizing signal transduction in dorsal root ganglion cells with IL-31 antagonists
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
EP2412727B1 (de) 2006-02-14 2016-06-29 University Of Tasmania Through The Menzies Research Institute Von Metallothionein abgeleitete Peptidfragmente
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
WO2007100711A2 (en) 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
EP1999148B8 (de) 2006-03-06 2014-03-05 Medlmmune, LLC Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
EP2377887A1 (de) 2006-03-10 2011-10-19 Zymogenetics Inc IL-17A- und IL-17F-bindende Antikörper und Verfahren zur ihrer Anwendung
HUE030105T2 (en) 2006-03-15 2017-04-28 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobin uptake with complement inhibitor
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
EP2010569A4 (de) 2006-03-20 2009-09-09 Xoma Technology Ltd Für gastrin spezifische humane antikörper, materialien und methoden
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
EP2389946A1 (de) 2006-03-23 2011-11-30 Novartis AG Antitumorzellenantigen-Antikörper-Therapeutika
EP4342995A3 (de) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
EP4218801A3 (de) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifizierungsverfahren zur reinigung eines bispezifischen antikörpers
US9321838B2 (en) 2006-04-10 2016-04-26 Fusion Antibodies Limited Therapy targeting cathepsin S
EP2082645A1 (de) 2006-04-19 2009-07-29 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
EP3255149A3 (de) 2006-05-02 2018-04-18 Intrexon Actobiotics NV Mikrobielle intestinale verabreichung von fettsucht verwandten peptiden
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
CL2007001623A1 (es) 2006-06-06 2008-01-18 Genentech Inc Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US20100040600A1 (en) 2006-06-14 2010-02-18 Chugai Seiyaku Kabushiki Kaisha Agents for Promoting the Growth of Hematopoietic Stem Cells
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2008003319A1 (en) 2006-07-04 2008-01-10 Genmab A/S Cd20 binding molecules for the treatment of copd
WO2008007755A1 (fr) 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha inducteur de mort cellulaire
EP2046809B1 (de) 2006-07-19 2016-12-07 The Trustees Of The University Of Pennsylvania Wsx-1/il-27 als target für entzündungshemmende reaktionen
RU2009107277A (ru) 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
WO2008020586A1 (en) 2006-08-14 2008-02-21 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
EP2423231A3 (de) 2006-08-18 2012-05-30 Novartis AG PRLR-spezifischer Antikörper und Anwendung
JP4780405B2 (ja) * 2006-08-29 2011-09-28 アイシン精機株式会社 結合親和性を利用する被検物質の測定方法、及び被検物質の測定のための結合親和性解析の制御方法
EP2471816A1 (de) 2006-08-30 2012-07-04 Genentech, Inc. Multispezifische Antikörper
EP2380907B1 (de) 2006-09-05 2016-11-30 Alexion Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von antikörpervermittelten Neuropathien
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US9017684B2 (en) 2006-10-12 2015-04-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-EREG antibody
US20100061933A1 (en) 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
JP5676849B2 (ja) 2006-10-20 2015-02-25 中外製薬株式会社 抗ｈｂ−ｅｇｆ抗体を有効成分として含む癌治療剤
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
AU2007313822A1 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
JP5795833B2 (ja) 2006-10-27 2015-10-14 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． スフィンゴシン−１−リン酸と結合させるための組成物および方法
KR20090101886A (ko) 2006-11-13 2009-09-29 에프. 호프만-라 로슈 아게 암 질환 조절 항체
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CN101687032A (zh) 2006-12-07 2010-03-31 诺瓦提斯公司 抗ephb3的拮抗剂抗体
CN101663322A (zh) 2006-12-14 2010-03-03 株式会社未来创药研究所 抗紧密连接蛋白3单克隆抗体以及使用该抗体的癌症的治疗和诊断
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
TW200831538A (en) 2006-12-19 2008-08-01 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
AU2007353773A1 (en) 2006-12-22 2008-11-27 Dow Agrosciences Llc Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences
JP5618172B2 (ja) 2007-01-05 2014-11-05 国立大学法人東京大学 抗ｐｒｇ−３抗体を用いる癌の診断および治療
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
EP2111553B1 (de) 2007-01-24 2018-09-19 Carnegie Mellon University Optische biosensoren
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CA2677996C (en) 2007-02-09 2018-06-12 Eisai R&D Management Co., Ltd. Gaba neuron progenitor cell marker 65b13
EP2126087A4 (de) 2007-02-20 2010-10-27 Anaptysbio Inc Verfahren zur erstellung von bibliotheken und ihre verwendung
HRP20120611T1 (hr) 2007-02-23 2012-10-31 Schering Corporation Anti-il-23p19 antitijela proizvedena genetiäśkim inžinjerstvom
WO2008103702A2 (en) 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
EP2064242A1 (de) 2007-02-23 2009-06-03 Schering Corporation Gentechnisch hergestellte anti-il-23p19 antikörper
CN101951953A (zh) 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
NZ579297A (en) 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
EP2395025A1 (de) 2007-02-28 2011-12-14 Schering Corporation Gentechnisch hergestellte anti-il-23r-antikörper
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
EP1972639A3 (de) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
DK2644205T3 (en) 2007-04-12 2018-09-24 Brigham & Womens Hospital Inc Targeting ABCB5 for Cancer Therapy
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
CA2683145C (en) 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
CN101688213A (zh) 2007-04-27 2010-03-31 陶氏环球技术公司 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134643A2 (en) 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
MX2009011996A (es) 2007-05-07 2010-04-21 Medimmune Llc Anticuerpos anti-coestimulador inducible y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunologica.
EP2164992B1 (de) 2007-05-30 2016-05-04 Lpath, Inc. Zusammensetzungen und verfahren zur bindung von lysophosphatidinsäure
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA2690124A1 (en) 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement-associated disorders
US20100298156A1 (en) 2007-06-08 2010-11-25 Si Tuen Lee-Hoeflich Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2691075C (en) 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
BRPI0814060A2 (pt) * 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
RS52305B (en) 2007-07-16 2012-12-31 Genentech Inc. ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
EP2641618A3 (de) 2007-07-16 2013-10-23 Genentech, Inc. Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
SI2185198T1 (sl) 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
EP2188311B1 (de) 2007-08-14 2016-10-05 Ludwig Institute for Cancer Research Ltd. Auf den egf-rezeptor zielender, monoklonaler antikörper 175 und derivate und anwendungen davon
US9175015B2 (en) 2007-08-22 2015-11-03 Colorado School Of Mines Gold nanoparticle conjugates and uses thereof
CA2698357C (en) 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US7704508B2 (en) 2007-09-14 2010-04-27 New York Blood Center Babesia subtilisin
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2348052A3 (de) 2007-09-17 2011-10-26 The Regents of The University of California Auf Prostatazellen in situ abzielende internalisierende humane monoklonale Antikörper
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP2535349A1 (de) 2007-09-26 2012-12-19 UCB Pharma S.A. Antikörperfusionen mit Doppelspezifität
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
CN102533702A (zh) 2007-09-28 2012-07-04 普托拉制药有限公司 用于因子xa抑制剂的解毒剂和其使用方法
WO2009046388A1 (en) 2007-10-03 2009-04-09 United States Medical Research & Material Command Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines
US20110014196A1 (en) * 2007-10-03 2011-01-20 Covalys Biosciences Ag Drug Transfer into Living Cells
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
RU2010120674A (ru) 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
JP5237382B2 (ja) 2007-10-30 2013-07-17 ジェネンテック， インコーポレイテッド 陽イオン交換クロマトグラフィーによる抗体の精製
EP2209807A1 (de) 2007-11-08 2010-07-28 Genentech, Inc. Anti-faktor-b-antikörper und ihre verwendungen
AU2008324045B2 (en) 2007-11-09 2014-08-07 Affitech Research As Anti-VEGF antibody compositions and methods
EP2220116B1 (de) 2007-11-12 2012-09-05 Theraclone Sciences, Inc. Zusammensetzungen und verfahren zur therapie und diagnose von grippe
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
AR069333A1 (es) 2007-11-15 2010-01-13 Chugai Pharmaceutical Co Ltd Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos
EP2219602A1 (de) 2007-11-15 2010-08-25 Amgen, Inc Wässrige formulierung von mit antioxidantien stabilisiertem erythropoese-stimulierendem protein zur parenteralen verabreichung
EP2728017B1 (de) 2007-11-19 2016-08-24 Celera Corporation Lungenkrebsmarker und Verwendungen davon
EP2062920A3 (de) 2007-11-21 2009-06-17 Peter Hornbeck Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
CN101970689A (zh) 2007-11-29 2011-02-09 健泰科生物技术公司 炎性肠病的基因表达标志物
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
KR101840994B1 (ko) 2007-12-05 2018-03-21 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
GB0723797D0 (en) 2007-12-05 2008-01-16 Immunosolv Ltd Method
EP2067787A1 (de) 2007-12-06 2009-06-10 Boehringer Ingelheim International GmbH Verfahren zur Kontrolle von Insektenpopulationen
ES2626634T3 (es) 2007-12-19 2017-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
PT2391650E (pt) 2007-12-20 2015-01-14 Xoma Us Llc Métodos para o tratamento de gota
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
US8697434B2 (en) 2008-01-11 2014-04-15 Colorado School Of Mines Detection of phage amplification by SERS nanoparticles
CN101918450A (zh) 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
EP2085095B1 (de) 2008-01-17 2012-03-07 Philogen S.p.A. Kombination aus einem Anti-EDb-Fibronectin-Antikörper-IL-2-Fusionsprotein und einem B-Zellen bindenden Molekül, B-Zellen-Vorläufern und/oder deren krebserregendem Gegenspieler
EP2247618B1 (de) 2008-01-25 2014-06-11 Amgen, Inc Ferroportin-antikörper und anwendungsverfahren
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
EP2247620B1 (de) 2008-01-31 2016-05-18 Genentech, Inc. Anti-cd79b-antikörper und immunkonjugate sowie verfahren zu ihrer verwendung
MX2010009885A (es) 2008-03-10 2010-11-30 Theraclone Sciences Inc Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
EP2842575B1 (de) 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin mit einem Heilmittel bindenden Konjugat
EP2604280A3 (de) 2008-03-27 2013-10-16 ZymoGenetics, Inc. Zusammensetzungen und Verfahren zur Hemmung von PDGFR-beta und VEGF-A
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
US9441204B2 (en) 2008-04-03 2016-09-13 Colorado School Of Mines Compositions and methods for detecting Yersinia pestis bacteria
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
US20090258013A1 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CA2718975A1 (en) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
RS51975B (en) * 2008-04-11 2012-02-29 Emergent Product Development Seattle Llc. CD37 IMMUNOTHERAPEUTIC PRODUCT AND ITS COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC AGENTS
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
EP2116555A1 (de) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Verwendung eines spezifisch an ED-B Fibronectin bindenden radioaktiv markierten Moleküls bei einem Verfahren zur Behandlung von Hodgkin-Lymphom
US8680025B2 (en) 2008-05-09 2014-03-25 Akonni Biosystems, Inc. Microarray system
JP5490783B2 (ja) 2008-05-09 2014-05-14 アコーニ バイオシステムズ マイクロアレイシステム
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2728473A1 (en) 2008-06-20 2009-12-23 National University Corporation Okayama University Antibody against oxidized ldl/.beta.2gpi complex and use of the same
WO2009155932A2 (en) 2008-06-25 2009-12-30 H. Lundbeck A/S Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
RS53688B9 (sr) 2008-07-08 2020-01-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
ES2613841T3 (es) 2008-07-16 2017-05-26 Medical And Biological Laboratories Co., Ltd. Anticuerpo anti-CLCP1 humano y uso del mismo
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
AU2009274512A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
ES2978373T3 (es) 2008-08-14 2024-09-11 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
US8968705B2 (en) 2008-08-22 2015-03-03 Colorado School Of Mines Gold/lanthanide nanoparticle conjugates and uses thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
ES2628108T3 (es) 2008-09-03 2017-08-01 F. Hoffmann-La Roche Ag Anticuerpos multiespecíficos
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2927244A1 (de) 2008-09-19 2015-10-07 MedImmune, LLC Gegen DLL4 gerichtete Antikörper und ihre Verwendung
BRPI0918947A2 (pt) 2008-09-26 2015-12-01 Ucb Pharma Sa proteína de fusão de anticorpo
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
EP2349367A4 (de) 2008-10-09 2013-09-04 Tufts College Modifizierte seidenfilme mit glycerol
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP5775458B2 (ja) 2008-11-06 2015-09-09 グレンマーク ファーマシューティカルズ， エセ．アー． 抗α２インテグリン抗体を使用する処置
CA2742986C (en) 2008-11-07 2015-03-31 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US8329188B2 (en) 2008-11-12 2012-12-11 Theraclone Sciences, Inc. Human M2e peptide immunogens
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
WO2010056981A2 (en) 2008-11-13 2010-05-20 Massachusetts General Hospital Methods and compositions for regulating iron homeostasis by modulation bmp-6
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
ATE523603T1 (de) 2008-11-21 2011-09-15 Chimera Biotec Gmbh Konjugatkomplexe zum analytnachweis
EP2361085B9 (de) 2008-11-22 2019-01-02 F.Hoffmann-La Roche Ag Verwendung des anti-vegf-antikörpers in kombination mit chemotherapie zur behandlung von brustkrebs
KR101846554B1 (ko) 2008-12-04 2018-04-06 란케나우 인스티튜트 포 메디칼 리서치 수정체 섬유 질환의 치료 및 예방용 조성물 및 방법
RU2636023C2 (ru) 2008-12-09 2017-11-17 Дженентек, Инк. Антитела к pd-l1 и их применение для усиления функции т-клеток
US20120027722A1 (en) 2008-12-17 2012-02-02 Medical Research Council Hepatitis c virus combination therapy
WO2010071800A1 (en) 2008-12-19 2010-06-24 Schering Corporation Feed supplement for mammalian cell culture and methods of use
WO2010073972A1 (ja) 2008-12-22 2010-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｎｅｐｈ３を用いた膵臓前駆細胞の取得方法
US8846870B2 (en) 2008-12-22 2014-09-30 Chugai Seiyaku Kabushiki Kaisha Anti-HS6ST2 antibodies and uses thereof
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
JP6009733B2 (ja) 2008-12-25 2016-10-19 国立大学法人 東京大学 抗ｔｍ４ｓｆ２０抗体を用いた癌の診断と治療
RU2011131071A (ru) 2008-12-26 2013-02-10 Дзе Юниверсити Оф Токио Диагностика и лечение рака с помощью антитела против lgr7
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
GB0903168D0 (en) 2009-02-25 2009-04-08 Fusion Antibodies Ltd Diagnostic method and kit
CA2919467C (en) 2009-03-02 2018-04-17 Jan Paul Medema Antibodies against a proliferating inducing ligand (april)
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2230515B1 (de) 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivierung von Oberflächen nach Ligandenkupplung
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
MX347295B (es) 2009-03-20 2017-04-20 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
US20120121596A1 (en) 2009-03-20 2012-05-17 Germaine Fuh Bispecific anti-her antibodies
AU2010229479B2 (en) 2009-03-25 2013-03-28 Genentech, Inc. Novel anti-alpha5beta1 antibodies and uses thereof
AU2010229994B2 (en) 2009-03-25 2016-08-18 Genentech, Inc. Anti-FGFR3 antibodies and methods using same
EP2233496A1 (de) 2009-03-26 2010-09-29 Ruhr-Universität Bochum Fluoreszenzproteine
EP3604510B1 (de) 2009-03-30 2025-03-26 Alexion Pharmaceuticals, Inc. Gegenmittel für faktor-xa-inhibitoren und verfahren zur verwendung davon
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
SG174891A1 (en) 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
WO2010119691A1 (ja) 2009-04-16 2010-10-21 国立大学法人東京大学 抗tmprss11e抗体を用いた癌の診断と治療
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
RU2011151069A (ru) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Анти-axl антитело
EP2432803A2 (de) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Zusammensetzungen und verfahren zur therapie und diagnose von grippe
EP2432878B2 (de) 2009-05-20 2018-05-16 Novimmune SA Synthetische polypeptidbibliotheken und verfahren zur erzeugung natürlich diversifizierter polypeptidvarianten
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011005581A2 (en) 2009-06-24 2011-01-13 Lpath, Inc. Methods of increasing neuronal differntiation using antibodies to lysophoshatidic acid
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
CN102471381A (zh) 2009-07-07 2012-05-23 霍夫曼-拉罗奇有限公司 自身免疫性脱髓鞘疾病的诊断和治疗
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
EP2456890A1 (de) 2009-07-20 2012-05-30 Genentech, Inc. Genexpressionsmarker für morbus crohn
JP5665866B2 (ja) 2009-07-24 2015-02-04 アコーニ バイオシステムズＡｋｏｎｎｉ Ｂｉｏｓｙｓｔｅｍｓ フローセルデバイス
AR077594A1 (es) 2009-07-31 2011-09-07 Organon Nv Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
US20110027275A1 (en) 2009-07-31 2011-02-03 Napoleone Ferrara Inhibition of tumor metastasis
KR20190018041A (ko) 2009-08-06 2019-02-20 제넨테크, 인크. 단백질 정제 시의 바이러스 제거의 개선방법
JP5930542B2 (ja) 2009-08-11 2016-06-08 ジェネンテック， インコーポレイテッド グルタミンフリー細胞培養培地におけるタンパク質の生産
TW201431558A (zh) 2009-08-15 2014-08-16 建南德克公司 用於治療先前治療過之乳癌之抗-血管新生療法
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2011021381A1 (ja) 2009-08-17 2011-02-24 株式会社未来創薬研究所 抗hb-egf抗体を有効成分として含む医薬組成物
KR20150089096A (ko) 2009-08-17 2015-08-04 트라콘 파마수티칼즈, 인코포레이티드 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법
CA2770174A1 (en) 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
BR112012004823B1 (pt) 2009-09-03 2021-11-30 Merck Sharp & Dohme Corp Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
RU2012114005A (ru) 2009-09-11 2013-10-20 Те Гавернмент Оф Те Юнайтед Стейтс Оф Америка Эз Репризентед Бай Те Секретари Оф Те Департмент Хелт Энд Хьюман Сервисез Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US8535912B2 (en) 2009-10-15 2013-09-17 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
CN102648211B (zh) 2009-10-22 2015-04-01 霍夫曼-拉罗奇有限公司 抗hepsin抗体及其使用方法
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2322149A1 (de) 2009-11-03 2011-05-18 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Ischämie
MY162511A (en) 2009-11-04 2017-06-15 Merck Sharp & Dohme Engineered anti-tslp antibody
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP6173690B2 (ja) 2009-11-05 2017-08-02 ジェネンテック， インコーポレイテッド 異種ポリペプチドの分泌のための方法及び組成物
EP3275898B1 (de) 2009-11-05 2024-06-05 Osaka University Therapeutischer wirkstoff für autoimmunerkrankungen oder allergien sowie verfahren zum screening nach dem therapeutischen wirkstoff
EP2498817A2 (de) 2009-11-12 2012-09-19 F. Hoffmann-La Roche AG Verfahren zur förderung der dichte von dendritischen spikes
EP2501407A1 (de) 2009-11-20 2012-09-26 Amgen Inc. Anti-orai1-antigenbindende proteine und ihre verwendung
KR101790767B1 (ko) 2009-11-24 2017-10-26 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
CN103724432B (zh) 2009-11-30 2016-06-08 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
EP3778917A3 (de) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren
EP2513308B1 (de) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation von pilr zur behandlung immunerkrankungen
EP2516465B1 (de) 2009-12-23 2016-05-18 F.Hoffmann-La Roche Ag Anti-bv8 antikörper und deren verwendungen
GB0922553D0 (en) 2009-12-23 2010-02-10 Fusion Antibodies Ltd Prognostic marker
CA2785587A1 (en) 2009-12-23 2011-06-30 4-Antibody Ag Binding members for human cytomegalovirus
EP2338492A1 (de) 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
MA33989B1 (fr) 2010-01-15 2013-02-01 Kirin Amgen Inc Formulation d'anticorps et régimes thérapeutiques
DK2530091T3 (en) 2010-01-29 2018-05-28 Chugai Pharmaceutical Co Ltd ANTI-DLL3 ANTIBODY
JP5104996B2 (ja) 2010-01-29 2012-12-19 東レ株式会社 ポリ乳酸系樹脂シート
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
CN110227154A (zh) 2010-02-23 2019-09-13 霍夫曼-拉罗奇有限公司 用于治疗卵巢癌的抗血管发生疗法
CN102985113B (zh) 2010-02-23 2015-05-20 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
JPWO2011105573A1 (ja) 2010-02-26 2013-06-20 株式会社 未来創薬研究所 抗ｉｃａｍ３抗体およびその用途
JP5845171B2 (ja) 2010-03-04 2016-01-20 大日本住友製薬株式会社 炎症性腸疾患用薬剤
HRP20190751T1 (hr) 2010-03-22 2019-06-14 F. Hoffmann - La Roche Ag Pripravci i postupci korisni za stabilizaciju formulacija koje sadrže proteine
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
TWI586806B (zh) 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
EP2566893A1 (de) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP2566510A1 (de) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur reduzierung der viskosität von proteinhaltigen formulierungen
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9995679B2 (en) 2010-05-25 2018-06-12 Carnegie Mellon University Targeted probes of cellular physiology
SG185737A1 (en) 2010-05-25 2013-01-30 Genentech Inc Methods of purifying polypeptides
ES2606627T3 (es) 2010-05-28 2017-03-24 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos específicos anti-CD160 para el tratamiento de trastornos oculares basados en la neoangiogénesis
CA2801509A1 (en) 2010-06-02 2011-12-08 Dainippon Sumitomo Pharma Co., Ltd. Treatment drug for autoimmune diseases and allergic diseases
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
DK2580240T3 (en) 2010-06-14 2019-03-25 Lykera Biomed S A S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF
MY161390A (en) 2010-06-24 2017-04-14 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
CN103080135B (zh) 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
AU2011274528B2 (en) 2010-07-09 2015-04-23 Genentech, Inc. Anti-neuropilin antibodies and methods of use
AU2011280969A1 (en) 2010-07-23 2013-02-07 Trustees Of Boston University Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2013001632A (es) 2010-08-10 2013-06-05 Amgen Inc Ensayo de enlace objetivo in vitro de funcion doble para la deteccion de anticuerpos neutralizantes contra anticuerpos objetivo.
AU2011289275A1 (en) 2010-08-12 2013-02-21 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
EP2606362B1 (de) 2010-08-19 2015-09-30 Roche Diagniostics GmbH Assay zur messung der antikörperbindung an einen therapeutischen, monoklonalen antikörper
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP2609114B1 (de) 2010-08-24 2018-04-11 Abbott Laboratories Antikörper spezifisch für das hiv core protein und deren verwendung
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG10201506703VA (en) 2010-08-27 2015-10-29 Gilead Biologics Inc Antibodies To Matrix Metalloproteinase 9
EP4085924A1 (de) 2010-08-31 2022-11-09 Theraclone Sciences, Inc. Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
WO2012032043A1 (en) 2010-09-07 2012-03-15 Areva Med Llc 212 pb imaging
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
EP2619319A2 (de) 2010-09-20 2013-07-31 Progenika Biopharma, S.A. Marker für gelenksdyspasie, osteoarthritis und sekundären erkrankungen
CA2814780C (en) 2010-09-22 2017-05-16 Amgen Inc. Carrier immunoglobulins and uses thereof
US8865170B2 (en) 2010-09-28 2014-10-21 Sekisui Chemical Co., Ltd. Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier
KR102166408B1 (ko) 2010-09-29 2020-10-16 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
US10933173B2 (en) 2010-10-19 2021-03-02 Trustees Of Tufts College Silk fibroin-based microneedles and methods of making the same
KR20140014077A (ko) 2010-10-25 2014-02-05 리전츠 오브 더 유니버스티 오브 미네소타 교모세포종의 치료를 위한 치료 조성물
WO2012061129A1 (en) 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
MX357167B (es) 2010-10-27 2018-06-28 Univ New York State Res Found Composiciones que se dirigen al dominio extracelular soluble de e-caderina y metodos relacionados para terapia de cancer.
TW201250003A (en) 2010-11-01 2012-12-16 Genentech Inc Predicting progression to advanced age-related macular degeneration using a polygenic score
EP3205662A3 (de) 2010-11-10 2017-11-01 Laboratorios del Dr. Esteve S.A. Hoch immunogene hiv-p24-sequenzen
NO2644698T3 (de) 2010-11-17 2018-06-02
EP2640831A1 (de) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
KR101614997B1 (ko) 2011-01-10 2016-04-22 씨티 아틀란틱 엘티디. 종양 관련 항원 결합 항체를 포함하는 조합 요법
US9772329B2 (en) 2011-01-11 2017-09-26 The Governing Council Of The University Of Toronto Protein detection method
DK2665746T3 (en) 2011-01-17 2021-02-01 Lykera Biomed S A Antibodies against the s100p protein for the treatment and diagnosis of cancer
WO2012100835A1 (en) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Methods and compositions for the treatment of aids
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2673301A2 (de) 2011-02-09 2013-12-18 Cancer Research Technology Limited Frmd4a-antagonisten und ihre verwendung
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
JP2014506580A (ja) 2011-02-14 2014-03-17 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
CN103429256B (zh) 2011-03-02 2022-09-13 诺和诺德保健股份有限公司 凝血因子向活化的血小板上的tlt-1的靶向
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
JP5832559B2 (ja) 2011-03-10 2015-12-16 オメロス コーポレーション ｅｘｖｉｖｏにおける加速された抗体進化による抗ＦＮ１４モノクローナル抗体の生成
EP2685968A1 (de) 2011-03-15 2014-01-22 Theraclone Sciences, Inc. Zusammensetzungen und verfahren zur therapie und diagnose von grippe
UY33959A (es) 2011-03-16 2012-09-28 Amgen Inc INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7
EP2686014A1 (de) 2011-03-16 2014-01-22 Sanofi Verwendung eines antikörperähnlichen proteins mit dualer v-region
EP2500073A1 (de) 2011-03-17 2012-09-19 ChromaCon AG Verfahren zur Identifizierung und Reinigung von mehrfach spezifischen Polypeptiden
US10906934B2 (en) 2011-03-25 2021-02-02 Genentech, Inc. Protein purification methods
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
RU2633509C2 (ru) 2011-03-31 2017-10-12 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
WO2012135589A1 (en) 2011-03-31 2012-10-04 Genentech, Inc. Methods of administering beta7 integrin antagonists
CA2834734A1 (en) 2011-04-04 2012-10-11 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
US20140186340A1 (en) 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
US20140193420A1 (en) 2011-04-18 2014-07-10 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-itm2a antibody
WO2012145652A1 (en) 2011-04-20 2012-10-26 Trustees Of Tufts College Dynamic silk coatings for implantable devices
CA2833879C (en) 2011-04-21 2023-03-14 David L. Kaplan Compositions and methods for stabilization of active agents
SMT201700515T1 (it) 2011-05-02 2018-01-11 Millennium Pharm Inc Formulazione per anticorpo anti- 4 7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CA2834776A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
AU2012253896B2 (en) 2011-05-06 2016-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant immunotoxin targeting mesothelin
US10273291B2 (en) 2011-05-09 2019-04-30 Duke University Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
ES2895523T3 (es) 2011-05-17 2022-02-21 Univ Rockefeller Anticuerpos neutralizantes del virus de inmunodeficiencia humana y métodos de uso de los mismos
JP2014524891A (ja) 2011-06-03 2014-09-25 シーティー アトランティック リミテッド Ｍａｇｅａ３結合抗体
WO2012167143A1 (en) 2011-06-03 2012-12-06 Xoma Technology Ltd. Antibodies specific for tgf-beta
WO2012163771A1 (en) 2011-06-03 2012-12-06 Ct Atlantic Ltd. Magea3 binding antibodies
AU2012268013B2 (en) 2011-06-09 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
GB201109965D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
JP6334395B2 (ja) 2011-06-17 2018-05-30 ノヴォ ノルディスク アー／エス 侵食細胞の選択的排除
JP6157461B2 (ja) 2011-06-30 2017-07-05 ジェンザイム・コーポレーション Ｔ細胞活性化の阻害剤
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
EP3088005B1 (de) 2011-07-05 2019-01-02 biOasis Technologies Inc P97-antikörperkonjugate
CA3158257A1 (en) 2011-07-11 2013-01-17 Ichnos Sciences SA Antibodies that bind to ox40 and their uses
WO2013011059A1 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Antagonist antibodies against oscar
WO2013011063A1 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Antagonistic antibodies against oscar
WO2013011061A1 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Antagonistic antibodies against oscar
WO2013011062A2 (en) 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
ES2657743T3 (es) 2011-07-19 2018-03-06 Philogen S.P.A. Terapia secuencial con anti-CTLA-4 e IL-2 dirigida
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
KR102049817B1 (ko) 2011-08-01 2019-12-02 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
JP2014525412A (ja) 2011-08-17 2014-09-29 ジェネンテック， インコーポレイテッド 難治性腫瘍における血管新生の阻害
WO2013025936A1 (en) 2011-08-18 2013-02-21 Cornell University Detection and treatment of metastatic disease
US9550835B2 (en) 2011-08-23 2017-01-24 Chugai Seiyaku Kabushiki Kaisha Anti-DDR1 antibody having anti-tumor activity
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
GB201212550D0 (en) 2012-07-13 2012-08-29 Novartis Ag B cell assay
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
MY170725A (en) 2011-09-09 2019-08-27 Univ Osaka Dengue-virus serotype neutralizing antibodies
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
AU2012308591B2 (en) 2011-09-16 2017-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with less immunogenic B cell epitopes
KR102276528B1 (ko) 2011-09-30 2021-07-12 추가이 세이야쿠 가부시키가이샤 이온 농도 의존성 결합 분자 라이브러리
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CN107266577B (zh) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
EP2581388A1 (de) 2011-10-14 2013-04-17 Centre National de la Recherche Scientifique (CNRS) Antikörper gegen sPLA2-V und Gebrauch davon
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
WO2013065343A1 (ja) * 2011-10-31 2013-05-10 株式会社 島津製作所 非ペプチドヒンジ部含有フレキシブル抗体様分子
EP2773438B2 (de) 2011-11-02 2021-10-20 F. Hoffmann-La Roche AG Überstrom- und elutions-chromatographie
EP2776066B1 (de) 2011-11-07 2018-09-19 Universite Laval Rank-/rankl-antagonisten zur verwendung zur behandlung neuromuskulärer erkrankungen, genetischer myopathien und/oder nicht genetischer myopathien
US20140370094A1 (en) 2011-11-08 2014-12-18 Tufts University Silk-based scaffold platform for engineering tissue constructs
KR20200093073A (ko) 2011-11-09 2020-08-04 트러스티즈 오브 터프츠 칼리지 주사가능한 실크 피브로인 입자 및 그의 용도
US9492504B2 (en) 2011-11-09 2016-11-15 Trustees Of Tufts College Injectable silk fibroin foams and uses thereof
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
WO2013078170A1 (en) 2011-11-21 2013-05-30 Genentech, Inc. Purification of anti-c-met antibodies
WO2013078377A1 (en) 2011-11-23 2013-05-30 Igenica, Inc. Anti-cd98 antibodies and methods of use thereof
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
EP2602265A1 (de) 2011-12-07 2013-06-12 Centre National de la Recherche Scientifique (CNRS) Antikörper gegen Anti-sPLA2-X und Verwendungen damit
US9636398B2 (en) 2011-12-14 2017-05-02 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CN107459576A (zh) 2011-12-14 2017-12-12 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
CA2859761C (en) 2011-12-22 2023-06-20 President And Fellows Of Harvard College Compositions and methods for analyte detection
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
MX360453B (es) 2011-12-22 2018-11-01 Genentech Inc Cromatografia de membrana de intercambio ionico.
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
BR112014016154A8 (pt) 2011-12-29 2017-07-04 Tufts College funcionalização de biomateriais para controlar respostas à regeneração e inflamação
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
EP2802603A4 (de) 2012-01-09 2015-11-04 Scripps Research Inst Ultralange komplementaritätsbestimmungsbereiche und verwendungen davon
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US9512212B2 (en) 2012-01-11 2016-12-06 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
HRP20181087T1 (hr) 2012-01-27 2018-09-07 AbbVie Deutschland GmbH & Co. KG Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita
EP2809684A1 (de) 2012-01-31 2014-12-10 Genentech, Inc. Anti-ig-e m1'-antikörper und verwendungsverfahren dafür
BR112014019459B1 (pt) 2012-02-08 2023-04-18 Mcure Biosciences Inc Proteínas de ligação à cdim e usos das mesmas
EP2812357B1 (de) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Einzelketten-antikörper und andere heteromultimere
IN2014DN08011A (de) 2012-02-29 2015-05-01 Gilead Biologics Inc
SG10201610788VA (en) 2012-02-29 2017-03-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
JP2015511960A (ja) 2012-03-09 2015-04-23 ランケナー インスティテュート フォー メディカル リサーチ がんを治療するための組成物及び方法
EP2825652B1 (de) 2012-03-15 2018-09-05 Omeros Corporation Zusammensetzung und verfahren zur diversifizierung von zielsequenzen
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
CA2867464A1 (en) 2012-03-20 2013-09-26 Trustees Of Tufts College Silk reservoirs for drug delivery
EP2641916A1 (de) 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
EP2833900B1 (de) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Extrazelluläre matrix-metalloproteasen-induktor (emmprin)-peptide und bindende antikörper
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US20150056294A1 (en) 2012-04-13 2015-02-26 Trustees Of Tufts College Methods and compositions for preparing a silk microsphere
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
HK1207977A1 (en) 2012-04-25 2016-02-19 Trustees Of Tufts College Silk microspheres and methods for surface lubrication
CN107759686A (zh) 2012-05-30 2018-03-06 中外制药株式会社 靶组织特异性抗原结合分子
SG11201407859YA (en) 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
KR20150023711A (ko) 2012-06-15 2015-03-05 제넨테크, 인크. 항-pcsk9 항체, 제제, 투여, 및 사용 방법
CN104395339A (zh) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
BR112014028368A2 (pt) 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
EP2874650A4 (de) 2012-07-19 2016-03-23 Redwood Bioscience Inc Für cd22 spezifischer antikörper und verfahren zur verwendung davon
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
EP2880156B1 (de) 2012-07-31 2017-08-23 biOasis Technologies Inc Dephosphorylierte proteine lysosomaler speicherkrankheiten und verwendung davon
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
GB2507207A (en) 2012-08-16 2014-04-23 Ipierian Inc Treatment of Tauopathies
TWI606063B (zh) 2012-08-23 2017-11-21 艾澤西公司 結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CA2886002C (en) 2012-09-27 2020-06-09 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
CA2886422C (en) 2012-10-03 2022-12-13 Jason Baardsnes Methods of quantitating heavy and light chain polypeptide pairs
CA2886152C (en) 2012-10-03 2020-01-14 Philogen S.P.A. Antigens associated with inflammatory bowel disease
EP2903691B1 (de) 2012-10-05 2019-05-22 F.Hoffmann-La Roche Ag Verfahren zur diagnose und behandlung von entzündlicher darmerkrankung
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
ES2822135T3 (es) 2012-10-18 2021-04-29 Univ Rockefeller Anticuerpos anti-VIH ampliamente neutralizantes
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
HK1212356A1 (en) 2012-10-30 2016-06-10 吉联亚科学公司 Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
JP6109952B2 (ja) 2012-11-01 2017-04-05 アッヴィ・インコーポレイテッド 抗ｖｅｇｆ／ｄｌｌ４二重可変ドメイン免疫グロブリンおよびこれらの使用
HRP20220637T1 (hr) 2012-11-02 2022-06-24 Bioverativ Usa Inc. Protutijela anti-komplementa c1s i njihova upotreba
HUE036433T2 (hu) 2012-11-05 2018-07-30 Pfizer Spliceostatin analógok
SG11201503469WA (en) 2012-11-07 2015-06-29 Pfizer Anti-notch3 antibodies and antibody-drug conjugates
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
CN105051528A (zh) 2012-11-15 2015-11-11 弗·哈夫曼-拉罗切有限公司 离子强度介导的pH梯度离子交换色谱
EP2922870B1 (de) 2012-11-21 2019-08-07 The Governors of the University of Alberta Immunmodulatorische peptide und verfahren zur verwendung davon
LT2928923T (lt) 2012-12-10 2020-02-25 Biogen Ma Inc. Anti-kraujo dendritinių ląstelių antigeno 2 antikūnai ir jų panaudojimas
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
EP2767549A1 (de) 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26-Antikörper und Verwendungen davon
AR094873A1 (es) 2013-02-25 2015-09-02 Genentech Inc Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
ES2774549T3 (es) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragmentos de P97 y usos de los mismos
AU2014243783B2 (en) 2013-03-13 2018-12-13 Genentech, Inc. Antibody formulations
WO2014151917A1 (en) 2013-03-14 2014-09-25 Ffe Therapeutics Llc Compositions and methods for treating angiogenesis-related disorders
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
ES2759061T3 (es) 2013-03-15 2020-05-07 Biomolecular Holdings Llc Inmunoglobulina híbrida que contiene unión no peptidílica
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014140240A1 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
EA201591806A1 (ru) 2013-03-15 2016-01-29 Байоджен Ма Инк. Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
GB2525568B (en) 2013-03-15 2020-10-14 Abvitro Llc Single cell barcoding for antibody discovery
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP2976362B1 (de) 2013-03-19 2019-10-23 Beijing Shenogen Pharma Group Ltd. Antikörper und verfahren zur behandlung von östrogenrezeptor-assoziierten erkrankungen
EP2976109B1 (de) 2013-03-21 2018-07-25 Genisphere, LLC Zelluläre freisetzung von dna-interkalierenden wirkstoffen
AU2014241552B2 (en) 2013-03-27 2018-08-16 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP2983710B1 (de) 2013-04-09 2019-07-31 Annexon, Inc. Behandlungsverfahren für neuromyelitis optica
CN105873950A (zh) 2013-04-09 2016-08-17 莱克尔生物医学有限公司 用于治疗和诊断癌症的抗s100a7抗体
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2999717B1 (de) 2013-05-21 2018-08-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Behandlung von mastzellen-vermittelten erkrankungen
WO2014192915A1 (ja) 2013-05-30 2014-12-04 国立大学法人 千葉大学 抗ミオシン調節軽鎖ポリペプチド抗体を含む炎症疾患治療用組成物
ES2753419T3 (es) 2013-06-07 2020-04-08 Univ Duke Inhibidores del factor H del complemento
CA3173775A1 (en) 2013-06-10 2014-12-18 Ipierian, Inc. Methods of treating a tauopathy
CA2915033C (en) 2013-06-12 2023-08-29 The General Hospital Corporation Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
WO2014205187A1 (en) 2013-06-20 2014-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
TW201542591A (zh) 2013-06-24 2015-11-16 Chugai Pharmaceutical Co Ltd 含有以人源化抗Ｅｐｉｒｅｇｕｌｉｎ抗體爲有效成分的腺癌以外的非小細胞肺癌之治療劑
EP3016973A1 (de) 2013-07-05 2016-05-11 INSERM - Institut National de la Santé et de la Recherche Médicale Neuartige alternative splice-transkripte für ketten-alpha der mhc-klasse i (mica) und verwendungen davon
JP6462680B2 (ja) 2013-07-09 2019-01-30 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
WO2015006686A1 (en) 2013-07-12 2015-01-15 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR20250007687A (ko) 2013-07-16 2025-01-14 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
US10640574B2 (en) 2013-07-18 2020-05-05 Taurus Biosciences, Llc Humanized antibodies with ultralong complementary determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10000572B2 (en) 2013-08-01 2018-06-19 Université Catholique de Louvain Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody
HK1225621A1 (zh) 2013-08-01 2017-09-15 Agensys, Inc. 結合cd37蛋白的抗體藥物偶聯物(adc)
KR20160037989A (ko) 2013-08-02 2016-04-06 아두로 바이오테크 홀딩스, 유럽 비.브이. 면역 자극을 위한 cd27 효능제와 면역 체크포인트 억제의 조합
PE20160192A1 (es) 2013-08-12 2016-04-27 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
JP2016536326A (ja) 2013-08-29 2016-11-24 ユニバーシティ オブ コペンハーゲン 癌治療用抗ａｄａｍ１２抗体
CA2921639A1 (en) 2013-09-05 2015-03-12 Aduro Biotech Holdings, Europe B.V. Cd70-binding peptides and method, process and use relating thereto
CN105848746B (zh) 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2015035260A1 (en) 2013-09-06 2015-03-12 Theranos, Inc. Systems and methods for detecting infectious diseases
EP3044593A4 (de) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Krebstherapie
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
EP3043820A4 (de) 2013-09-13 2017-07-12 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden
PT3050896T (pt) 2013-09-27 2021-08-24 Chugai Pharmaceutical Co Ltd Processo para a produção de heteromultímeros de polipéptidos
GB201317207D0 (en) 2013-09-27 2013-11-13 Univ Glasgow Materials and methods for modulating disc1 turnover
MX2016003617A (es) 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
US9243294B2 (en) 2013-09-30 2016-01-26 Hadasit Medical Research Services And Development Ltd. Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
CN105849120A (zh) 2013-10-06 2016-08-10 美国卫生和人力服务部 修饰的假单胞菌外毒素a
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
EP3733868A3 (de) 2013-10-28 2021-01-13 DOTS Technology Corp. Allergennachweis
US20160297892A1 (en) 2013-11-07 2016-10-13 Novo Nordisk A/S Novel Methods and Antibodies for Treating Coagulapathy
PL3070168T3 (pl) 2013-11-11 2024-10-28 Chugai Seiyaku Kabushiki Kaisha Cząsteczka wiążąca antygen zawierająca zmodyfikowany region zmienny przeciwciała
WO2015073633A1 (en) 2013-11-15 2015-05-21 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
EP3072527B1 (de) 2013-11-20 2022-03-09 National University Corporation Hokkaido University Immunsuppressiionsmittel
EP2876114A1 (de) 2013-11-25 2015-05-27 Consejo Superior De Investigaciones Científicas Antikörper gegen CCR9 und Anwendungen davon
US10081679B2 (en) 2013-11-25 2018-09-25 Ccam Biotherapeutics Ltd. Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
EP3663763B1 (de) 2013-11-26 2022-02-16 The Brigham and Women's Hospital, Inc. Zusammensetzungen und verfahren zur modulierung einer immunreaktion
CN105899230B (zh) 2013-11-27 2020-06-09 伊皮埃里安股份有限公司 治疗tau病变的方法
CN109917125A (zh) 2013-12-03 2019-06-21 哈佛大学董事会 用于评估妊娠糖尿病的方法和试剂
US10961530B2 (en) 2013-12-04 2021-03-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
CA2931113C (en) 2013-12-20 2023-07-11 Genentech, Inc. Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them
BR112016014293B1 (pt) 2013-12-20 2023-11-21 Intervet International B.V Região de fragmento cristalizável canino, anticorpo caninizado, e,composição farmacêutica
EP3581179A1 (de) 2013-12-27 2019-12-18 Chugai Seiyaku Kabushiki Kaisha Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
JP2017502672A (ja) 2013-12-30 2017-01-26 メディシナル バイオコンバージェンス リサーチ センター 抗ｋｒｓモノクロナル抗体及びこれの用途
EP2896400A1 (de) 2014-01-17 2015-07-22 Université Catholique De Louvain Verfahren zur Erhöhung der Bioverfügbarkeit von inhaliertem Verbindungen
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
RU2701434C2 (ru) 2014-01-24 2019-09-26 Нгм Биофармасьютикалс, Инк. Связывающие белки и способы их применения
RU2669807C2 (ru) 2014-01-27 2018-10-16 Пфайзер Инк. Бифункциональные цитотоксические агенты
EP3102608B1 (de) 2014-02-03 2019-09-18 Bioasis Technologies Inc. P97-fusionsproteine
US10106623B2 (en) 2014-02-12 2018-10-23 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
EP3110847A1 (de) 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antikörper gegen matrix-metalloproteinase 9 und verfahren zur verwendung davon
JP6538707B2 (ja) 2014-03-07 2019-07-03 ユニバーシティ ヘルス ネットワーク 免疫応答を調節するための方法及び組成物
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
EP3119913B1 (de) 2014-03-21 2021-01-06 The Brigham and Women's Hospital, Inc. Verfahren und zusammensetzungen zur behandlung von immunbedingten erkrankungen oder störungen und/oder therapieüberwachung
WO2015145449A2 (en) 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
KR20160138494A (ko) 2014-03-31 2016-12-05 데비오팜 인터네셔날 에스 에이 Fgfr 융합물
PL3126391T3 (pl) 2014-03-31 2020-05-18 Universitetet I Tromsø - Norges Arktiske Universitet Przeciwciała przeciwko HPA-1a
US9995746B2 (en) 2014-04-02 2018-06-12 The United States Of America, As Represented By The Secretary Of The Army Rapid dual direct fluorescent antibody assay for the identification of Bacillus antrhacis
JP6789117B2 (ja) 2014-04-25 2020-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫媒介性疾患を有する対象を処置するための組成物および方法
WO2015164364A2 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
AP2016009504A0 (en) 2014-04-27 2016-10-31 Ccam Biotherapeutics Ltd Humanized antibodies against ceacam1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP4306544A3 (de) 2014-05-06 2024-03-20 F. Hoffmann-La Roche AG Herstellung heteromultimerer proteine unter verwendung von säugetierzellen
US10584171B2 (en) 2014-05-30 2020-03-10 Henlix Biotech Co., Ltd. Anti-epidermal growth factor receptor (EGFR) antibodies
HRP20210250T1 (hr) 2014-06-09 2021-04-02 Ultragenyx Pharmaceutical Inc. Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
AU2015274987A1 (en) 2014-06-11 2016-11-24 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
EP3169361B1 (de) 2014-07-15 2019-06-19 F.Hoffmann-La Roche Ag Zusammensetzungen zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und mek-inhibitoren
WO2016023019A2 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
ES2921875T3 (es) 2014-08-11 2022-09-01 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
TW201609099A (zh) 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
WO2016026143A1 (en) 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US20160137727A1 (en) 2014-09-15 2016-05-19 Genentech, Inc. Antibody formulations
TW201620938A (zh) 2014-09-15 2016-06-16 安美基公司 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
EP3536786B1 (de) 2014-09-15 2021-06-30 AbVitro LLC Nukleotidbibliotheksequenzierung mit hohem durchsatz
PL3110447T3 (pl) 2014-09-16 2020-10-19 Synermore Biologics Co., Ltd. Przeciwciało anty-EGFR i jego zastosowania
EP3197915A4 (de) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanisierte anti-hepcidin-antikörper und verwendungen davon
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
PT3215527T (pt) 2014-11-05 2025-02-27 Annexon Inc Anticorpos anti-fator do complemento c1q humanizados e as suas utilizações
BR112017008666A2 (pt) 2014-11-05 2018-01-30 Genentech, Inc. anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
BR112017008628A2 (pt) 2014-11-06 2018-01-30 Genentech Inc terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
MY185114A (en) 2014-11-07 2021-04-30 Sesen Bio Inc Improved il-6 antibodies
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
EP3217787B1 (de) 2014-11-10 2019-04-17 F.Hoffmann-La Roche Ag Tiermodell für nephropathie und mittel zur behandlung davon
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
PT3218005T (pt) 2014-11-12 2023-04-11 Seagen Inc Compostos que interagem com glicano e métodos de uso
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
BR112017010268B1 (pt) 2014-11-19 2024-01-16 P & M Venge Ab Agente de ligação, composição de diagnóstico, kit de diagnóstico, método de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral, métodos para descartar uma infecção bacteriana ou viral em um indivíduo, métodos para considerar uma infecção bacteriana ou viral em um indivíduo, método para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo, método para descartar uma doença infecciosa, método para identificação do tipo de infecção e dispositivo para o diagnóstico de infecções bacterianas
WO2016081808A1 (en) 2014-11-20 2016-05-26 The Regents Of The University Of California Compositions and methods related to hematologic recovery
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
WO2016090148A1 (en) 2014-12-03 2016-06-09 IsoPlexis Corporation Analysis and screening of cell secretion profiles
JP2017537929A (ja) 2014-12-05 2017-12-21 ジェネンテック， インコーポレイテッド Ｐｄ−１軸アンタゴニスト及びｈｐｋ１アンタゴニストを用いたがん治療のための方法及び組成物
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3229909B1 (de) 2014-12-11 2020-10-14 Inbiomotion S.L. Bindeelemente für menschliches c-maf
WO2016097420A1 (en) 2014-12-19 2016-06-23 Universite De Nantes Anti il-34 antibodies
EP3916017A1 (de) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1-antikörper
US10610504B2 (en) 2014-12-23 2020-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Alpha-cell re-generation combined with conversion to beta cells
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
PT3250230T (pt) 2015-01-28 2021-12-07 Ra Pharmaceuticals Inc Moduladores da atividade do complemento
HK1245882A1 (zh) 2015-01-28 2018-08-31 F. Hoffmann-La Roche Ag 多發性硬化的基因表達標志和治療
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3253796A1 (de) 2015-02-03 2017-12-13 Université Catholique de Louvain Anti-garp-protein und verwendungen davon
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
TW202446796A (zh) 2015-02-05 2024-12-01 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
EP3253865B1 (de) 2015-02-06 2022-06-22 National University of Singapore Verfahren zur verbesserung der wirksamkeit therapeutischer immunzellen
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
WO2016137985A1 (en) 2015-02-26 2016-09-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
MX2017010336A (es) 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
MX387454B (es) 2015-03-06 2025-03-18 Genentech Inc DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EP3271402B1 (de) 2015-03-16 2021-04-28 Aarhus Universitet Antikörper gegen ein extrazelluläres region nbcn1
US10780179B2 (en) 2015-03-18 2020-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
US10688119B2 (en) 2015-03-20 2020-06-23 Aarhus Universitet Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
JP6782250B2 (ja) 2015-03-20 2020-11-11 ファイザー・インク Ｃｔｉファーマコフォアを含有する二官能性細胞毒性剤
EP3277306B1 (de) 2015-04-01 2023-02-22 Hadasit Medical Research Services and Development Ltd. Inhibitoren der neuroligin-4-neurexin-1-beta-protein-protein-wechselwirkung zur verwendung in der behandlung von lebererkrankungen
EP3279216A4 (de) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von polypeptid-hetero-oligomer
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
SG11201707490SA (en) 2015-04-03 2017-10-30 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
HUE061076T2 (hu) 2015-04-06 2023-05-28 Bioverativ Usa Inc Humanizált anti-C1s ellenanyagok alkalmazási eljárások
EP3280433B1 (de) 2015-04-06 2021-09-15 Subdomain, LLC De-novo-bindungsdomäne mit polypeptiden und verwendungen davon
MX393951B (es) 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
HK1249532A1 (zh) 2015-04-07 2018-11-02 F. Hoffmann-La Roche Ag 具有激動劑活性的抗原結合複合體及使用方法
EP3081575A1 (de) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium-parasiten-antikörper
CN107454906B (zh) 2015-04-17 2022-05-27 豪夫迈·罗氏有限公司 使用凝固因子和多特异性抗体的联合治疗
JP7044553B2 (ja) 2015-04-24 2022-03-30 ジェネンテック， インコーポレイテッド 結合ポリペプチドを含む細菌を特定する方法
EP4238994A3 (de) 2015-05-11 2024-02-07 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur behandlung von lupus nephritis
US10787517B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
US10787516B2 (en) 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
EP3154439A1 (de) 2015-05-19 2017-04-19 Yaya Diagnostics GmbH Mittel und verfahren zur anreicherung von nukleinsäuren
CA3025145A1 (en) 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
US20180134788A1 (en) 2015-05-26 2018-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
EP3795679A1 (de) 2015-05-28 2021-03-24 Genentech, Inc. Zellbasierter test zum nachweis von anti-cd3-homodimeren
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
HK1253694A1 (zh) 2015-06-01 2019-06-28 Medigene Immunotherapies Gmbh T細胞受體文庫
AU2016273214B2 (en) 2015-06-01 2018-10-18 Medigene Immunotherapies Gmbh Method for generating antibodies against T cell receptor
CA2987877A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
US11136390B2 (en) 2015-06-12 2021-10-05 Alector Llc Anti-CD33 antibodies and methods of use thereof
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016280003B2 (en) 2015-06-16 2021-09-16 Merck Patent Gmbh PD-L1 antagonist combination treatments
JP2018520153A (ja) 2015-06-29 2018-07-26 ジェネンテック， インコーポレイテッド 臓器移植における使用のためのｉｉ型抗ｃｄ２０抗体
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
KR101750411B1 (ko) 2015-07-10 2017-06-27 한국생명공학연구원 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US11273167B2 (en) 2015-08-03 2022-03-15 The Regents Of The University Of California Compositions and methods for modulating ABHD2 activity
PT3331553T (pt) 2015-08-05 2022-07-27 Inst Nat Sante Rech Med Novos anticorpos anti-gpvi humana e utilizações dos mesmos
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017021023A1 (en) 2015-08-06 2017-02-09 Yaya Diagnostics Gmbh Means and methods for the detection of targets
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
IL257062B (en) 2015-08-11 2022-07-01 Wuxi Biologics Cayman Inc Novel anti-pd-1 antibodies
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
AU2016316730B2 (en) 2015-09-02 2023-05-25 Immutep S.A.S. Anti-LAG-3 Antibodies
EP3344658B1 (de) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Anti tigit (human t-cell immunoglobulin and itim domain) antikörper
EP4223784A3 (de) 2015-09-02 2023-10-04 The Regents of the University of Colorado, a body corporate Zusammensetzungen und verfahren zur modulation der t-zell-vermittelten immunantwort
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CA2998174A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
US11078251B2 (en) 2015-09-18 2021-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) T cell receptors (TCR) and uses thereof for the diagnosis and treatment of diabetes
CN113372443A (zh) 2015-09-18 2021-09-10 中外制药株式会社 Il-8-结合抗体及其应用
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
DK3353196T5 (da) 2015-09-22 2024-09-30 Inst Nat Sante Rech Med Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
SG10201911226QA (en) 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies
AU2016326738B2 (en) 2015-09-24 2023-08-31 Abvitro Llc HIV antibody compositions and methods of use
WO2017050955A1 (en) 2015-09-24 2017-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Agents capable of inhibiting the binding between leptin and vegf165
AU2016326737B2 (en) 2015-09-24 2023-01-12 Abvitro Llc Affinity-oligonucleotide conjugates and uses thereof
IL319106A (en) 2015-09-25 2025-04-01 Genentech Inc Anti-TIGIT antibodies and methods of use
EP3353550A1 (de) 2015-09-25 2018-08-01 AbVitro LLC Hochdurchsatzverfahren für t-zell-rezeptorzielidentifizierung von nativ gepaarten t-zell rezeptorsequenzen
ES2839212T3 (es) 2015-09-29 2021-07-05 Inst Nat Sante Rech Med Métodos para determinar el estado metabólico de linfomas B
EP3356415B1 (de) 2015-09-29 2024-05-01 Amgen Inc. Asgr-inhibitoren
CN108289953B (zh) 2015-09-29 2022-03-11 细胞基因公司 Pd-1结合蛋白及其使用方法
EP3355902B1 (de) 2015-09-30 2022-04-13 Merck Patent GmbH Kombination eines pd-1-achsen-bindungsantagonisten und eines alk-inhibitors zur behandlung von alk-negativem krebs
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
CN108738323B (zh) 2015-10-06 2023-05-26 艾利妥 抗trem2抗体及其使用方法
EP3362088B1 (de) 2015-10-12 2020-11-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Zur verringerung von cd8-t-zellen fähiger wirkstoff zur behandlung von myokardinfarkt oder akutem myokardinfarkt
EP3362093A4 (de) 2015-10-13 2019-05-08 Technion Research & Development Foundation Limited Heparanase-neutralisierende monoklonale antikörper
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
WO2017075432A2 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2017075212A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
AU2016349897B2 (en) 2015-11-03 2021-11-04 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
JP6983779B2 (ja) 2015-11-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 非常に特異的な腫瘍細胞表面抗原を標的とするヒト抗体を用いた腫瘍特異的ペイロード送達及び免疫活性化
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
BR112018012164A2 (pt) 2015-12-15 2018-12-04 Gilead Sciences Inc anticorpos neutralizantes do vírus da imunodeficiência humana
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
AU2016370210A1 (en) 2015-12-16 2018-06-21 Ra Pharmaceuticals, Inc. Modulators of complement activity
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
US10588953B2 (en) 2015-12-18 2020-03-17 Agilvax, Inc. Compositions and methods related to xCT peptides
EP3395366B1 (de) 2015-12-21 2023-11-22 Hefei Lifeon Pharmaceutical Co., Ltd. Wirkstoffdesignverfahren, erhaltener wirkstoff und anwendung davon
CN108603171A (zh) 2015-12-23 2018-09-28 基因医疗免疫疗法有限责任公司 新一代抗原-特异性tcr
JP6954842B2 (ja) 2015-12-25 2021-10-27 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
US20200264165A1 (en) 2016-01-04 2020-08-20 Inserm (Institut National De La Sante Et De Larecherche Medicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
US11306140B2 (en) 2016-01-07 2022-04-19 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
JP7078536B2 (ja) 2016-01-08 2022-05-31 アルトゥルバイオ， インコーポレイテッド 四価抗ｐｓｇｌ－１抗体とその使用
HUE052893T2 (hu) 2016-01-13 2021-05-28 Acerta Pharma Bv Antifolát és BTK-gátló terápiás kombinációi
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
WO2017129558A1 (en) 2016-01-25 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
US11513127B2 (en) 2016-01-25 2022-11-29 Genentech, Inc. Methods for assaying T-cell dependent bispecific antibodies
US11028410B2 (en) 2016-01-27 2021-06-08 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
WO2017129790A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancer
JP6902040B2 (ja) 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
US10723727B2 (en) 2016-02-01 2020-07-28 Pfizer Inc. Tubulysin analogs and methods for their preparation
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
IL260983B (en) 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
KR20180116359A (ko) 2016-02-23 2018-10-24 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 제제 및 이의 용도
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
KR102812377B1 (ko) 2016-03-01 2025-05-23 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
US11340219B2 (en) 2016-03-17 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-pY1235-MET immunological binding reagent
EP3433277A4 (de) 2016-03-23 2020-06-17 Mabspace Biosciences (Suzhou) Co., Ltd Neuartige anti-pd-l1-antikörper
BR112018069273A2 (pt) 2016-03-25 2019-01-22 Seattle Genetics Inc métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco
AU2017241524B2 (en) 2016-03-28 2021-07-08 Incyte Corporation Pyrrolotriazine compounds as TAM inhibitors
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
AU2017240233B2 (en) 2016-03-31 2022-07-14 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
US10934347B2 (en) 2016-04-04 2021-03-02 Genzyme Corporation Anti-complement factor BB antibodies and uses thereof
US20200330459A1 (en) 2016-04-06 2020-10-22 Inserm (Institut National De La Santé Et La Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
EP3440113A1 (de) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Zusammensetzungen und verfahren zur behandlung von krebs, entzündungs- und autoimmunerkrankungen
EP3442991A4 (de) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. Ras-bindende peptide und verfahren zur verwendung
EP3445393A4 (de) 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. Cmv-neutralisierende antigenbindende proteine
WO2017182609A1 (en) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
ES2820173T3 (es) 2016-05-06 2021-04-19 Inst Nat Sante Rech Med Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente
JP7537074B2 (ja) 2016-05-10 2024-08-21 ソルボンヌ ウニベルシテ Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
EP3463452A1 (de) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von nicht-kleinzelligem lungenkrebs (nsclc), der mit chronisch obstruktiver lungenerkrankung (copd) koexistiert
MX2018014435A (es) 2016-05-26 2019-04-15 Merck Patent Gmbh Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer.
WO2017202890A1 (en) 2016-05-27 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating myeloma
MA45234A (fr) 2016-06-14 2019-04-17 Adimab Llc Anticorps anti-facteur xi de coagulation
SG11201810777WA (en) 2016-06-17 2018-12-28 Genentech Inc Purification of multispecific antibodies
DK3264087T3 (da) 2016-06-27 2020-07-20 Chimera Biotec Gmbh Fremgangsmåde og indretning til kvantificering af målmolekyler
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US10519250B2 (en) 2016-08-01 2019-12-31 Xoma (Us) Llc Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US11712480B2 (en) 2016-08-03 2023-08-01 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
JP7161266B2 (ja) 2016-08-05 2022-10-26 メディミューン，エルエルシー 抗ｏ２抗体およびその使用
EP3494139B1 (de) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
CA3033737A1 (en) 2016-08-15 2018-02-22 Genentech, Inc. Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
MX388593B (es) 2016-08-15 2025-03-20 Novartis Ag Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
SG11201901961SA (en) 2016-09-06 2019-04-29 Chugai Pharmaceutical Co Ltd Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
EP3510046A4 (de) 2016-09-07 2020-05-06 The Regents of the University of California Antikörper gegen oxidationsspezifische epitope
WO2018049418A1 (en) 2016-09-12 2018-03-15 IsoPlexis Corporation System and methods for multiplexed analysis of cellular and other immunotherapeutics
HUE054571T2 (hu) 2016-09-14 2021-09-28 Merck Patent Gmbh Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
JP6854342B2 (ja) 2016-09-15 2021-04-07 ノビミューン エスアー ファージ表面上での二重特異性抗体の提示
AU2017327828B2 (en) 2016-09-16 2023-11-16 Shanghai Henlius Biotech, Inc. Anti-PD-1 antibodies
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
EA201990747A1 (ru) 2016-09-19 2019-10-31 Способы лечения иммунных нарушений с применением белков, связывающих pd–1
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
AU2017329799A1 (en) 2016-09-20 2019-04-11 Aarhus Universitet Compounds for treatment of lipoprotein metabolism disorders
WO2018055031A1 (en) 2016-09-21 2018-03-29 Aarhus Universitet Acid-base transport inhibitors
ES2873377T3 (es) 2016-09-22 2021-11-03 Inst Nat Sante Rech Med Procedimientos y composiciones farmacéuticas para el tratamiento de cáncer de pulmón
AU2017332495A1 (en) 2016-09-24 2019-04-11 Abvitro Llc Affinity-oligonucleotide conjugates and uses thereof
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018058111A1 (en) 2016-09-26 2018-03-29 The Brigham And Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インターロイキン２に結合する抗体およびその使用
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
CA3036717A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing gfap status in patient samples
EP3523330A1 (de) 2016-10-04 2019-08-14 Fairbanks Pharmaceuticals, Inc. Anti-fstl3-antikörper und verwendungen davon
US11274154B2 (en) 2016-10-06 2022-03-15 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
WO2018077926A1 (en) 2016-10-25 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
ES2908239T3 (es) 2016-10-28 2022-04-28 Astute Medical Inc Uso de anticuerpos contra timp-2 para la mejora de la función renal
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
WO2018081805A1 (en) 2016-10-31 2018-05-03 Sofregen Medical, Inc. Compositions comprising low molecular weight silk fibroin fragments and plasticizers
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US11493508B2 (en) 2016-11-11 2022-11-08 IsoPlexis Corporation Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP3541847A4 (de) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
IL300095A (en) 2016-11-23 2023-03-01 Translational Drug Dev Llc Benzamide and tumor necrosis factor receptor superfamily agonist compositions and uses thereof
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
US20200081010A1 (en) 2016-12-02 2020-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing renal cell carcinoma
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
CN110291107B (zh) 2016-12-22 2023-05-05 卡坦扎罗麦格纳格拉西亚大学 靶向cd43的独特唾液酸糖基化的癌症相关表位的单克隆抗体
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
CA3049105A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Dnabii vaccines and antibodies with enhanced activity
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
KR20190104048A (ko) 2017-01-06 2019-09-05 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
JP7664020B2 (ja) 2017-01-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
TW201831517A (zh) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
WO2018138591A1 (en) 2017-01-24 2018-08-02 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
AU2018214222C1 (en) 2017-02-03 2021-08-05 Acticor Biotech Inhibition of platelet aggregation using anti-human GPVI antibodies
WO2018148585A1 (en) 2017-02-10 2018-08-16 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR20190128676A (ko) 2017-03-14 2019-11-18 바이오버라티브 유에스에이 인코포레이티드 보체-매개된 질환 및 장애의 치료 방법
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
ES2989063T3 (es) 2017-03-15 2024-11-25 Cue Biopharma Inc Combinación de polipéptidos de fusión multiméricos e inhibidor del punto de control inmunitario para el tratamiento de cáncer asociado a HPV
EP3596126A4 (de) 2017-03-15 2021-03-03 Tsinghua University Neuartige anti-trkb-antikörper
WO2018175752A1 (en) 2017-03-22 2018-09-27 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
EP3600441A1 (de) 2017-03-22 2020-02-05 Genentech, Inc. Hydrogelvernetzte hyaluronsäure-prodrug-zusammensetzungen und verfahren
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
EP3600443A1 (de) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Verfahren zur herstellung von glucuronidwirkstoff-linkern und zwischenprodukten davon
US12161694B2 (en) 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
EP3600427A1 (de) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und zusammensetzungen zur behandlung von melanom
WO2018178030A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
WO2018178029A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
MX2019011657A (es) 2017-03-30 2019-11-18 Merck Patent Gmbh Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
US20210275543A1 (en) 2017-03-30 2021-09-09 Nserm (Institut National De La Santé Et De La Recherche Médicale) Methods for the treatment of mitochondrial genetic diseases
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2018189381A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating lung cancers
BR112019021472A8 (pt) 2017-04-14 2023-05-02 Inst Curie Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres
SG11201909516VA (en) 2017-04-14 2019-11-28 Tollnine Inc Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CN110546513A (zh) 2017-04-15 2019-12-06 雅培实验室 使用早期生物标记物帮助超急性诊断和确定人类受试者中的创伤性脑损伤的方法
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
SG11201909708VA (en) 2017-04-21 2019-11-28 Mellitus Llc Methods and antibodies for diabetes-related applications
EP3615569A1 (de) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
KR20240067275A (ko) 2017-04-26 2024-05-16 유레카 쎄라퓨틱스, 인코포레이티드 글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
SG11201909395TA (en) 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
BR112019023409A2 (pt) 2017-05-10 2020-06-16 Iovance Biotherapeutics, Inc. Métodos para tratar um câncer em um paciente e uma malignidade hematológica, para expandir linfócitos infiltrantes de tumor, linfócitos de sangue periférico e linfócitos infiltrantes de medula, processo para a preparação de uma população de linfócitos infiltrantes de tumor, e, uso de um tumor líquido na fabricação de uma população de linfócitos infiltrantes de tumor.
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
EP3625258A1 (de) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5-antikörper und verfahren zur verwendung davon
CN110651190A (zh) 2017-05-25 2020-01-03 雅培实验室 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
CN111148849A (zh) 2017-05-26 2020-05-12 阿布维托有限责任公司 高通量多核苷酸文库测序和转录组分析
BR112019025387A2 (pt) 2017-05-30 2020-07-07 Abbott Laboratories métodos para auxiliar no diagnóstico e avaliação de uma lesão traumática cerebral branda em um indivíduo humano com o uso de troponina cardíaca i e biomarcadores precoces
EP3638218A4 (de) 2017-06-14 2021-06-09 The Broad Institute, Inc. Zusammensetzungen und verfahren zum targeting von komplementierender komponente 3 zur hemmung des tumorwachstums
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
EP3641802A1 (de) 2017-06-22 2020-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von fibrose mit mitteln zur hemmung der aktivierung von mukosa-assoziierten invarianten t-zellen (mait)
CN110799544A (zh) 2017-06-27 2020-02-14 达纳-法伯癌症研究所有限公司 用于鉴别并治疗白血病中对于cta4拮抗剂的耐药性的组合物和方法
WO2019002548A1 (en) 2017-06-29 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
WO2019010299A1 (en) 2017-07-06 2019-01-10 Memorial Sloan Kettering Cancer Center DOTA-HAPTENE COMPOSITIONS FOR RADIOIMMUNOTHERAPY PRECIBLED BY A BISPECIFIC ANTIGEN ANTI-DOTA / ANTI-TUMOR ANTIBODY
WO2019014044A1 (en) 2017-07-12 2019-01-17 The Johns Hopkins University ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
EP3655430A1 (de) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose und behandlung von hepatitis-b-virusinfektionen
WO2019016310A1 (en) 2017-07-20 2019-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND COMPOSITIONS FOR TREATING CANCERS
WO2019018729A1 (en) 2017-07-20 2019-01-24 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2019020593A1 (en) 2017-07-25 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
WO2019020807A1 (en) 2017-07-28 2019-01-31 Gene Signal International Sa CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
US11285149B2 (en) 2017-07-28 2022-03-29 Dana-Farber Cancer Institute, Inc. Enhanced immunotherapy of cancer using targeted transcriptional modulators
JP2020533948A (ja) 2017-08-03 2020-11-26 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
JP7299160B2 (ja) 2017-08-03 2023-06-27 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
US11085929B2 (en) 2017-08-31 2021-08-10 Arizona Board Of Regents On Behalf Of Arizona State University Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
AU2018338418B2 (en) 2017-09-19 2025-06-05 Cdrd Ventures Inc. Anti-HLA-A2 antibodies and methods of using the same
CA3076547A1 (en) 2017-09-20 2019-03-28 The University Of British Columbia Novel anti-hla-a2 antibodies and uses thereof
CN111655340A (zh) 2017-09-20 2020-09-11 国家医疗保健研究所 用于调节自噬的方法和药物组合物
WO2019063958A1 (en) 2017-09-27 2019-04-04 The University Of York BIOCONJUGATION OF POLYPEPTIDES
RS62872B1 (sr) 2017-09-27 2022-02-28 Incyte Corp Soli derivata pirrolotriazina korisne kao tam inhibitori
SG10202007194PA (en) 2017-09-29 2020-08-28 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
CN111148759B (zh) 2017-09-30 2023-09-19 合肥立方制药股份有限公司 结合至纤维连接蛋白b结构域的蛋白
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
CN111447934A (zh) 2017-10-06 2020-07-24 4阵营疗法公司 用于治疗尿素循环障碍的方法和组合物，尤其是otc缺乏症
EP3694552A1 (de) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap-antikörper und verwendungen davon
JP2020536967A (ja) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
EP3700567A4 (de) 2017-10-26 2021-09-29 The Regents of The University of California Hemmung von oxidationsspezifischen epitopen zur behandlung von ischämischen reperfusionsschäden
GB201717966D0 (en) 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
JP2021502125A (ja) 2017-11-09 2021-01-28 ピンテオン セラピューティクス インコーポレイテッド ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物
WO2019099433A2 (en) 2017-11-14 2019-05-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
AU2018369784B2 (en) 2017-11-14 2023-06-01 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
AU2018367524B2 (en) 2017-11-17 2022-09-15 Merck Sharp & Dohme Llc Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
WO2019101995A1 (en) 2017-11-27 2019-05-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for cardiac regeneration
WO2019102456A1 (en) 2017-11-27 2019-05-31 University Of Rijeka Faculty Of Medicine Immunotoxins for treating cancer
WO2019113506A1 (en) 2017-12-07 2019-06-13 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
EP3721233A2 (de) 2017-12-09 2020-10-14 Abbott Laboratories Verfahren zur unterstützung bei der diagnose und bewertung eines patienten, der eine orthopädische verletzung erlitten hat und der eine verletzung des kopfes wie eine leichte traumatische hirnverletzung (tbi) hat oder möglicherweise erlitten hat, unter verwendung eines glialen fibrillären sauren proteins (gfap) und/oder einer ubiquitin-carboxy-terminalen hydrolase l1 (uch-l1)
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
JP7565795B2 (ja) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
EP3498293A1 (de) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
KR20200100147A (ko) 2017-12-19 2020-08-25 더 락커펠러 유니버시티 개선된 이펙터 기능을 갖는 사람 IgG Fc 도메인 변이체
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
WO2019129211A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
EP3732489A1 (de) 2017-12-29 2020-11-04 Abbott Laboratories Neuartige biomarker und verfahren zur diagnose und bewertung von traumatischer hirnverletzung
US20210072244A1 (en) 2018-01-04 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
JP2021510594A (ja) 2018-01-25 2021-04-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
PE20211304A1 (es) 2018-02-09 2021-07-20 Genentech Inc Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
EP3752196A4 (de) 2018-02-15 2022-03-23 MacroGenics, Inc. Cd3-bindende domänenvarianten und ihre verwendung in kombinationstherapien zur behandlung von krankheiten
CA3091311A1 (en) 2018-02-16 2019-08-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of antagonists of cxcr3b for treating vitiligo
EP3755712A1 (de) 2018-02-21 2020-12-30 Cell Design Labs, Inc. Chimäre transmembranrezeptoren und verwendungen davon
JP7391027B2 (ja) 2018-02-26 2023-12-04 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体による治療のための投薬
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019179420A1 (en) 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
AU2019241350A1 (en) 2018-03-30 2020-07-30 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
EP3774883A1 (de) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antikörper und fragmente davon, die hepatitis-b-virus-protein x binden
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
CN113384711A (zh) 2018-04-13 2021-09-14 基因泰克公司 稳定的抗cd79b免疫缀合物制剂
CN112292400A (zh) 2018-04-13 2021-01-29 桑格摩生物治疗法国公司 对白介素-23受体特异的嵌合抗原受体
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
US12235273B2 (en) 2018-05-04 2025-02-25 Abbott Laboratories HBV diagnostic, prognostic, and therapeutic methods and products
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
AU2019264229A1 (en) 2018-05-04 2020-12-03 Merck Patent Gmbh Combined inhibition of PD-1/PD-L1, TGFβ and DNA-PK for the treatment of cancer
JP2021522801A (ja) 2018-05-09 2021-09-02 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトネクチン４に特異的な抗体
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
TWI816396B (zh) 2018-05-23 2023-09-21 美商輝瑞大藥廠 特異性針對gucy2c之抗體及其用途
KR102602329B1 (ko) 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
US12129485B2 (en) 2018-05-23 2024-10-29 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
GB201808927D0 (en) 2018-05-31 2018-07-18 Institute Of Cancer Res Royal Cancer Hospital Materials and methods for monitoring the development of resistance of cancers to treatment
CA3106380A1 (en) 2018-05-31 2019-12-05 Glyconex Inc. Therapeutic antibodies
CN112533952B (zh) 2018-06-01 2023-03-07 大有华夏生物医药集团有限公司 治疗疾病或病况的组合物及其用途
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
KR20210016390A (ko) 2018-06-01 2021-02-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
JP7382970B2 (ja) 2018-06-08 2023-11-17 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
SG11202012342WA (en) 2018-06-18 2021-01-28 Eureka Therapeutics Inc Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
EP4349411A3 (de) 2018-06-20 2024-06-19 Incyte Corporation Anti-pd-1-antikörper und verwendungen davon
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
EP3818083A2 (de) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
CN118063599A (zh) 2018-07-03 2024-05-24 吉利德科学公司 靶向hiv gp120的抗体和使用方法
BR112021000075A2 (pt) 2018-07-05 2021-04-06 Incyte Corporation Derivados de pirazina fundidos como inibidores de a2a/a2b
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
AU2019246837B2 (en) 2018-07-13 2024-03-21 Alector Llc Anti-Sortilin antibodies and methods of use thereof
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
US12258398B2 (en) 2018-07-27 2025-03-25 Alector Llc Anti-Siglec-5 antibodies and methods of use thereof
MD3830120T3 (ro) 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Noi proteine de fuziune specifice pentru CD137 și PD-L1
KR20210046006A (ko) 2018-08-10 2021-04-27 상가모 테라퓨틱스 프랑스 Tnfr2 도메인을 포함하는 신규한 car 작제물
WO2020037174A1 (en) 2018-08-16 2020-02-20 The Johns Hopkins University Antibodies to human znt8
BR112021002826A2 (pt) 2018-08-16 2021-05-04 Biontech Us Inc. construtos de receptor de célula t e usos dos mesmos
KR20210052468A (ko) 2018-08-27 2021-05-10 피어이스 파마슈티컬즈 게엠베하 Cd137/her2 이중특이적 제제 및 pd-1 축 억제제를 포함하는 조합물 치료요법 및 이의 용도
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
AR119259A1 (es) 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
EP3848397A4 (de) 2018-09-04 2022-07-20 Nanjing Umab-Biopharma Co., Ltd. Fusionsprotein und seine verwendung zur herstellung von arzneimitteln zur behandlung von tumoren und/oder virusinfektionen
WO2020052543A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
US20220047567A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
CN113396160A (zh) 2018-09-19 2021-09-14 国家医疗保健研究所 治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
WO2020061429A1 (en) 2018-09-20 2020-03-26 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
EP3626265A1 (de) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-cd45rc-antikörper und verwendungen davon
EP3856772A1 (de) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von antagonisten von th17-zytokinen zur behandlung von bronchialer remodellierung bei patienten mit allergischem asthma
CA3113798A1 (en) 2018-09-27 2020-04-02 Celgene Corporation Sirp.alpha. binding proteins and methods of use thereof
US20210380675A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
JP7592585B2 (ja) 2018-10-04 2024-12-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 粘膜炎症性疾患の処置のための方法及び医薬組成物
WO2020073004A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Compositions and methods for enzymatic disruption of bacterial biofilms
WO2020074937A1 (en) 2018-10-09 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
WO2020077236A1 (en) 2018-10-12 2020-04-16 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
AU2019373090B2 (en) 2018-10-31 2023-05-25 The University Of Sydney Compositions and methods for treating viral infections
WO2020092937A1 (en) 2018-11-02 2020-05-07 Annexon, Inc. Compositions and methods for treating brain injury
US12343380B2 (en) 2018-11-05 2025-07-01 Iovance Biotherapeutics, Inc. Expansion of TILs utilizing AKT pathways inhibitors
WO2020096989A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
GB201818618D0 (en) 2018-11-15 2019-01-02 Amlo Biosciences Ltd Monoclonal antibodies against ambra-1
GB201818622D0 (en) 2018-11-15 2019-01-02 Amlo Biosciences Ltd Monoclonal antibodies against loricrin
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
TW202034956A (zh) 2018-12-03 2020-10-01 美商艾澤西公司 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US12234292B2 (en) 2018-12-20 2025-02-25 Kyowa Kirin Co., Ltd. FN14 antibodies and uses thereof
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020146740A1 (en) 2019-01-10 2020-07-16 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
CN118878685A (zh) 2019-01-13 2024-11-01 耶路撒冷希伯来大学伊森姆研究发展有限公司 特异性针对人类连接蛋白-2的抗体
US11680105B2 (en) 2019-01-17 2023-06-20 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
EP3917957A1 (de) 2019-01-28 2021-12-08 Maple Biotech LLC Psmp-antagonisten zur verwendung bei der behandlung von fibrotischen erkrankungen der lunge, niere oder leber
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
MX2021009831A (es) 2019-02-15 2021-09-10 Integral Molecular Inc Anticuerpos claudina 6 y usos de los mismos.
WO2020168024A1 (en) 2019-02-15 2020-08-20 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
EP3924458A1 (de) 2019-02-15 2021-12-22 Just-Evotec Biologics, Inc. Automatisierte bioherstellungssysteme, anlagen und prozesse
WO2020171020A1 (ja) 2019-02-18 2020-08-27 株式会社エヌビィー健康研究所 細胞の選抜方法、核酸の製造方法、組換え細胞の製造方法、目的物質の製造方法、医薬組成物の製造方法、及び試薬
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
BR112021016829A2 (pt) 2019-02-26 2021-10-19 Pieris Pharmaceuticals Gmbh Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres
AU2020228383A1 (en) 2019-02-27 2021-09-23 Genentech, Inc. Dosing for treatment with anti-tigit and anti-CD20 or anti-CD38 antibodies
AU2020233284A1 (en) 2019-03-01 2021-09-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
BR112021016984A2 (pt) 2019-03-01 2021-11-30 Allogene Therapeutics Inc Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
WO2020178313A1 (en) 2019-03-05 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarkers and biotargets in renal cell carcinoma
WO2020185763A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
US20220143148A1 (en) 2019-03-14 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
US20220152148A1 (en) 2019-03-18 2022-05-19 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
EP3943108A4 (de) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
WO2020193441A1 (en) 2019-03-22 2020-10-01 Université de Paris New inhibitors of lrrk2/pp1 interaction
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
EP3946330A1 (de) 2019-03-29 2022-02-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von keloid, hypertrophischen narben und/oder hyperpigmentierungserkrankungen
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CA3133652A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
BR112021019701A2 (pt) 2019-04-02 2021-12-14 Kenjockety Biotechnology Inc Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220175815A1 (en) 2019-04-03 2022-06-09 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
BR112021020116A2 (pt) 2019-04-08 2021-12-07 Biogen Ma Inc Anticorpos anti-integrina e usos dos mesmos
CN114025757B (zh) 2019-04-18 2025-05-13 Qlsf生物治疗药物公司 人源化抗pd-l1抗体
JP2022528804A (ja) 2019-04-18 2022-06-15 ジェネンテック， インコーポレイテッド 抗体力価試験
US20220220565A1 (en) 2019-04-30 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP3962924A1 (de) 2019-05-03 2022-03-09 Genentech, Inc. Verfahren zur verminderung der enzymatischen hydrolyseaktivitätsrate in einer aus einer reinigungsplattform erhaltenen zusammensetzung
GB201906302D0 (en) 2019-05-03 2019-06-19 Amlo Biosciences Ltd Methods of determining the margin of a tumour
GB201906297D0 (en) 2019-05-03 2019-06-19 Amlo Biosciences Ltd Biomarkers for disease progression in squamous cell carcinoma
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
PE20220764A1 (es) 2019-05-10 2022-05-16 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco
WO2020234399A1 (en) 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies
KR20220010544A (ko) 2019-05-21 2022-01-25 노파르티스 아게 Cd19 결합 분자 및 이의 용도
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
JP7664183B2 (ja) 2019-05-21 2025-04-17 ノバルティス アーゲー Ｂｃｍａに対する三重特異性結合分子及びその使用
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
WO2020240360A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
GB2598520B (en) 2019-05-28 2024-07-24 Univ Shanghai Technology Composition and methods to treat ectodermal dysplasia 2, Clouston type
EP3976643A2 (de) 2019-05-30 2022-04-06 Amgen Inc. Engineering des gelenkbereichs zur steuerung der dimerisierung von antikörpern
WO2020243661A1 (en) 2019-05-31 2020-12-03 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
JP2022535553A (ja) 2019-06-04 2022-08-09 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗ｃｅａｃａｍ５モノクローナル抗体、その作製方法およびその使用
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
US20220253669A1 (en) 2019-06-07 2022-08-11 Chugai Seiyaku Kabushiki Kaisha Information processing system, information processing method, program, and method for producing antigen-binding molecule or protein
US20220363770A1 (en) 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
EP3999538A1 (de) 2019-07-15 2022-05-25 Intervet International B.V. Caninisierte antikörper gegen canines ctla-4
KR20220034807A (ko) 2019-07-16 2022-03-18 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd38에 대해 특이성을 갖는 항체 및 이의 용도
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
MX2022001133A (es) 2019-08-01 2022-04-25 Incyte Corp Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
EP4007584A1 (de) 2019-08-02 2022-06-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Neutralisierung von granzym b zur bereitstellung von herzprotektion bei einem patienten, der einen myokardinfarkt erleidet
GB201911210D0 (en) 2019-08-06 2019-09-18 Amlo Biosciences Ltd Clinical management of oropharyngeal squamous cell carcinoma
US20220308072A1 (en) 2019-08-12 2022-09-29 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
TW202118512A (zh) 2019-09-12 2021-05-16 美商建南德克公司 治療狼瘡性腎炎之組成物及方法
US20220348687A1 (en) 2019-09-20 2022-11-03 Genentech, Inc. Dosing for anti-tryptase antibodies
EP4034561A2 (de) 2019-09-27 2022-08-03 Starkage Therapeutics Mit seneszenten zellen assoziierte antigen-bindende domänen, antikörper und chimäre antigenrezeptoren damit sowie deren verwendungen
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
TW202126690A (zh) 2019-09-27 2021-07-16 美商建南德克公司 用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
WO2021063968A1 (en) 2019-09-30 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for diagnosing chronic obstructive pulmonary disease
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
WO2021064180A1 (en) 2019-10-03 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
EP4037710A1 (de) 2019-10-04 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzung zur behandlung von eierstockkrebs, brustkrebs oder bauchspeicheldrüsenkrebs
JP7671284B2 (ja) 2019-10-04 2025-05-01 ティーエーイー ライフ サイエンシーズ Ｆｃ変異および部位特異的コンジュゲーション特性を含む抗体組成物
GB201914399D0 (en) 2019-10-04 2019-11-20 Univ Newcastle Biomarkers for assessing explant organ viability
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
EP4045124A4 (de) 2019-10-15 2024-01-24 Sofregen Medical, Inc. Abgabevorrichtungen für die abgabe und verfahren zur abgabe von zusammensetzungen
EP3808766A1 (de) 2019-10-15 2021-04-21 Sangamo Therapeutics France Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor
EP3812008A1 (de) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-kompetitiver antagonistischer antikörper
AU2020379176A1 (en) 2019-11-04 2022-06-09 Pieris Pharmaceuticals Gmbh HER2/4-1BB bispecific fusion proteins for the treatment of cancer
AU2020378335A1 (en) 2019-11-05 2022-04-07 Merck Patent Gmbh Anti-TIGIT antibodies and uses thereof
CN115066613A (zh) 2019-11-06 2022-09-16 基因泰克公司 用于治疗血液癌症的诊断和治疗方法
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
US20230037414A1 (en) 2019-11-22 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
IL293386A (en) 2019-12-05 2022-07-01 Alector Llc Methods of use of anti-trem2 antibodies
EP4073117A1 (de) 2019-12-10 2022-10-19 Institut Pasteur Neuer antikörper, der menschliche fcgriiia und fcgriiib blockiert
GB201918103D0 (en) 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
MX2022007156A (es) 2019-12-12 2022-09-07 Alector Llc Metodos de uso de anticuerpos anti-cd33.
PH12022551298A1 (en) 2019-12-17 2023-11-20 Pfizer Antibodies specific for cd47, pd-l1, and uses thereof
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods of treating iga nephropathy with atrasentan
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN115551595A (zh) 2020-01-03 2022-12-30 因赛特公司 Cd73抑制剂和a2a/a2b腺苷受体抑制剂组合疗法
CN115279766B (zh) 2020-01-03 2025-05-02 因赛特公司 包含a2a/a2b和pd-1/pd-l1抑制剂的组合疗法
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
US20230076415A1 (en) 2020-01-17 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021154761A1 (en) 2020-01-27 2021-08-05 Genentech, Inc. Methods for treatment of cancer with an anti-tigit antagonist antibody
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20230203156A1 (en) 2020-01-29 2023-06-29 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
EP4106767A1 (de) 2020-02-21 2022-12-28 Université de Liège Erschöpfung der ext1-expression und/oder -aktivität verbessert die zelluläre produktion von biologischen entitäten
EP4110814A1 (de) 2020-02-24 2023-01-04 Alector LLC Verfahren zur verwendung von anti-trem2-antikörpern
EP4110388A1 (de) 2020-02-24 2023-01-04 Oblique Therapeutics AB Kras-epitope und antikörper
EP4110810A1 (de) 2020-02-28 2023-01-04 Orega Biotech Kombinationstherapien auf basis von ctla4- und il-17b-inhibitoren
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN115551894A (zh) 2020-03-12 2022-12-30 以明生物免疫医疗公司 新型抗lilrb4抗体和衍生产物
US11760797B2 (en) 2020-03-13 2023-09-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
JP2023518538A (ja) 2020-03-20 2023-05-02 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） ヒトｃｄ４５ｒｃに特異的なキメラ抗原受容体およびその使用
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
MX2022012182A (es) 2020-04-03 2022-12-08 Alector Llc Metodos de uso de anticuerpos anti-trem2.
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
AU2021253899A1 (en) 2020-04-06 2022-11-17 University Of Rijeka Faculty Of Medicine Antibodies to NKp46 and constructs thereof for treatment of cancers and infections
WO2021204878A1 (en) 2020-04-08 2021-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cdon inhibitors for the treatment of endothelial dysfunction
EP4132971A1 (de) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinitätsgereifte anti-lap-antikörper und verwendungen davon
EP4136459A1 (de) 2020-04-13 2023-02-22 Abbott Laboratories Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
MX2022012752A (es) 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
US20230165836A1 (en) 2020-04-21 2023-06-01 Université Catholique de Louvain Alpha-2 adrenergic receptor agonists for the treatment of cancer
EP4138802A1 (de) 2020-04-21 2023-03-01 Université catholique de Louvain Alpha-2-adrenerge rezeptoragonisten zur vorbeugung und/oder behandlung von milzleiden
EP4139449A1 (de) 2020-04-22 2023-03-01 Fabmid Verfahren zur zirkularisierung linearer doppelsträngiger nukleinsäuren
JP2023523145A (ja) 2020-04-27 2023-06-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポ蛋白（ａ）に対するイソ型非依存性抗体
JP2023524464A (ja) 2020-04-30 2023-06-12 サイロパ ビー．ブイ． 抗ｃｄ１０３抗体
WO2021224401A1 (en) 2020-05-07 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for determining a reference range of β-galactose exposure platelet
AU2021270458A1 (en) 2020-05-13 2022-11-10 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis
GB202007312D0 (en) 2020-05-18 2020-07-01 Synthetic Vac Ltd Mimotope peptides of the spike protein from the sars-cov-2 virus
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4157881A4 (de) 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antikörper, die spezifisch den nervenwachstumsfaktor erkennen, und deren verwendungen
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
EP4161564A1 (de) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Multispezifische antikörper gegen abcg2-effluxpumpen-krebsantigen und zusammensetzungen, reagenzien, kits und verfahren im zusammenhang damit
EP4161650A1 (de) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Anti-abcg2-antikörper und verwendungen davon
KR20230020443A (ko) 2020-06-05 2023-02-10 피어이스 파마슈티컬즈 게엠베하 4-1bb 표적화 다량체 면역조절제
WO2021245224A1 (en) 2020-06-05 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating ocular diseases
GB202008651D0 (en) 2020-06-09 2020-07-22 Univ Newcastle Method of identifying complement modulators
MX2022015881A (es) 2020-06-18 2023-01-24 Genentech Inc Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
CN113912706A (zh) 2020-07-09 2022-01-11 北京凯因科技股份有限公司 结合乙型肝炎病毒表面抗原的抗体及其应用
IL299586A (en) 2020-07-16 2023-03-01 Novartis Ag Anti-betacellulin antibodies, their fragments, and multispecific binding molecules
JP2023535610A (ja) 2020-07-28 2023-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンを予防及び処置するための方法及び組成物
WO2022031749A1 (en) 2020-08-03 2022-02-10 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
WO2022031576A1 (en) 2020-08-03 2022-02-10 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
US20230323299A1 (en) 2020-08-03 2023-10-12 Inserm (Institut National De La Santé Et De La Recherch Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
MX2023001625A (es) 2020-08-07 2023-05-16 Fortis Therapeutics Inc Inmunoconjugados que se dirigen a cd46 y metodos de uso de los mismos.
WO2022040466A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
WO2022044010A1 (en) 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
EP4208477A1 (de) 2020-09-01 2023-07-12 Merck Patent GmbH Nkp30-bindemittel
EP4208483A1 (de) 2020-09-02 2023-07-12 Kenjockety Biotechnology, Inc. Anti-abcc1-antikörper und verwendungen davon
EP3970752A1 (de) 2020-09-17 2022-03-23 Merck Patent GmbH Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
US20230366884A1 (en) 2020-09-18 2023-11-16 Pieris Pharmaceuticals Gmbh Biomarker methods and uses
WO2022058539A1 (en) 2020-09-18 2022-03-24 Ichnos Sciences SA Cd47-cd38 bispecific antibodies
WO2022061214A1 (en) 2020-09-21 2022-03-24 Genentech, Inc. Purification of multispecific antibodies
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
EP4225330A1 (de) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076474A2 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
EP3981789A1 (de) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb-antikörper und verwendungen davon
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022079209A1 (en) 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
AU2021362007A1 (en) 2020-10-16 2023-06-22 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
WO2022094116A1 (en) 2020-10-30 2022-05-05 Genentech, Inc. Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate
US20230416816A1 (en) 2020-11-03 2023-12-28 IsoPlexis Corporation Methods and devices for mulitplexed proteomic and genetic analysis and on-device preparation of cdna
EP4240761A1 (de) 2020-11-05 2023-09-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von il-6-inhibitoren zur behandlung des akuten brustsyndroms bei patienten mit sichelzellanämie
EP4240494A1 (de) 2020-11-06 2023-09-13 Novartis AG Anti-cd19-mittel und auf b-zellen abzielende kombinationstherapie zur behandlung von b-zell-malignomen
EP4240491A1 (de) 2020-11-06 2023-09-13 Novartis AG Cd19-bindende moleküle und verwendungen davon
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
EP4244246A1 (de) 2020-11-10 2023-09-20 Amgen Inc. Neue linker von multispezifischen antigenbindenden domänen
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
EP4244391A1 (de) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom
AR124123A1 (es) 2020-11-20 2023-02-15 Inst Nat Sante Rech Med Anticuerpos anti-cd25
US20240002521A1 (en) 2020-11-20 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
CA3198161A1 (en) 2020-12-01 2022-06-09 Beth MCQUISTON Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
GB202019522D0 (en) 2020-12-10 2021-01-27 Oblique Therapeutics Ab Epitopes and antibodies
JP2024501452A (ja) 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
AU2021403010A1 (en) 2020-12-16 2023-07-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
AU2021411952A1 (en) 2020-12-29 2023-08-10 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024501845A (ja) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
EP4266991A4 (de) 2021-01-29 2025-01-01 The Regents of University of California Implantierbare bildgebungsvorrichtungen zur in-vivo-bildgebung
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
IL304904A (en) 2021-02-01 2023-10-01 St Phi Therapeutics Co Ltd Targeted protein degradation system and use thereof
AU2022219681A1 (en) 2021-02-11 2023-09-21 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
WO2022178255A2 (en) 2021-02-19 2022-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
WO2022178253A1 (en) 2021-02-19 2022-08-25 IsoPlexis Corporation Methods and devices for spatially resolved analysis of proteomic and genetic information
US20240141026A1 (en) 2021-03-04 2024-05-02 Centre National De La Recherche Scientifique Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
TW202300014A (zh) 2021-03-05 2023-01-01 美商艾歐凡斯生物治療公司 腫瘤儲存及細胞培養組成物
EP4294927A2 (de) 2021-03-10 2023-12-27 Immunowake Inc. Immunmodulatorische moleküle und verwendungen davon
TW202300521A (zh) 2021-03-15 2023-01-01 美商建南德克公司 治療狼瘡性腎炎的組成物及方法
US20240165094A1 (en) 2021-03-17 2024-05-23 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
JP2024510505A (ja) 2021-03-19 2024-03-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法
AU2022241940A1 (en) 2021-03-23 2023-10-26 Pieris Pharmaceuticals Gmbh Her2/4-1bb bispecific fusion proteins for the treatment of cancer
US20240175873A1 (en) 2021-03-23 2024-05-30 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
CA3213080A1 (en) 2021-03-23 2022-09-29 Krit RITTHIPICHAI Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
JP2024515564A (ja) 2021-04-08 2024-04-10 ピエリス ファーマシューティカルズ ゲーエムベーハー 結合組織増殖因子（ｃｔｇｆ）に特異的な新規リポカリンムテイン
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
EP4320153A1 (de) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von anaplastischem grosszelligem lymphom
WO2022219152A1 (en) 2021-04-16 2022-10-20 Oblique Therapeutics Ab Kras antibodies
EP4326871A1 (de) 2021-04-19 2024-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von splice-switching-oligonukleotiden zum exon-skipping-vermittelten knockdown von pim2
TW202308669A (zh) 2021-04-19 2023-03-01 美商艾歐凡斯生物治療公司 嵌合共刺激性受體、趨化激素受體及彼等於細胞免疫治療之用途
CN117651714A (zh) 2021-04-20 2024-03-05 美国安进公司 多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
WO2022223824A1 (en) 2021-04-23 2022-10-27 Philogen S.P.A Anti-fibroblast activation protein antibodies
US20240158861A1 (en) 2021-04-23 2024-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
EP4340850A1 (de) 2021-05-17 2024-03-27 Iovance Biotherapeutics, Inc. Pd-1-geneditierte tumorinfiltrierende lymphozyten und verwendungen davon in der immuntherapie
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
JP2024519858A (ja) 2021-05-18 2024-05-21 アボット・ラボラトリーズ 小児対象における脳損傷を査定する方法
EP4342913A4 (de) 2021-05-19 2024-11-20 Shanghai Escugen Biotechnology Co., Ltd. Chimäres antigenrezeptormolekül zur spezifischen erkennung von baff-r und anwendung eines chimären antigenrezeptormoleküls
US12252550B2 (en) 2021-05-20 2025-03-18 Dianthus Therapeutics Opco, Inc. Antibodies that bind to C1S and uses thereof
US20250199013A1 (en) 2021-05-28 2025-06-19 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
AU2021451307A1 (en) 2021-06-16 2024-02-01 Shanghai Sinobay Biotechnology Co., Ltd. Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof
IL309579A (en) 2021-06-22 2024-02-01 Merck Patent Gmbh VHH-based NKP30 binders
AU2022304582A1 (en) 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023275394A1 (en) 2021-07-02 2023-01-05 Merck Patent Gmbh Anti-protac antibodies and complexes
US20240309095A1 (en) 2021-07-07 2024-09-19 Incyte Corporation Anti-b7-h4 antibodies and uses thereof
WO2023283611A1 (en) 2021-07-08 2023-01-12 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
EP4370555A1 (de) 2021-07-13 2024-05-22 TrueBinding, Inc. Verfahren zur verhinderung von proteinaggregation
JP2024525769A (ja) 2021-07-14 2024-07-12 舒泰神（北京）生物製薬股フン有限公司 Ｃｄ４０を特異的に認識する抗体およびその使用
US20240318114A1 (en) 2021-07-15 2024-09-26 Just-Evotec Biologics, Inc. Bidirectional tangential flow filtration (tff) perfusion system
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
EP4377333A2 (de) 2021-07-30 2024-06-05 Institut National de la Santé et de la Recherche Médicale (INSERM) Chimäre proteine und verfahren zur immuntherapie
WO2023017149A1 (en) 2021-08-13 2023-02-16 Oblique Therapeutics Ab Thioredoxin 1 antibodies
CN117897409A (zh) 2021-08-13 2024-04-16 基因泰克公司 抗类胰蛋白酶抗体的给药
EP4388103A1 (de) 2021-08-20 2024-06-26 Tallac Therapeutics, Inc. Nectin-4-antikörper und konjugate
EP4392783A1 (de) 2021-08-27 2024-07-03 Abbott Laboratories Verfahren zum nachweis von immunoglobulin g, subklassen 4 (igg4) in einer biologischen probe
WO2023034809A1 (en) 2021-08-30 2023-03-09 Lassen Therapeutics 1, Inc. Anti-il-11rα antibodies
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
AU2022343729A1 (en) 2021-09-09 2024-03-21 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
EP4401842A1 (de) 2021-09-16 2024-07-24 Aboleris Pharma Anti-human-cd45rc-bindungsdomänen und verwendungen davon
JP2024534581A (ja) 2021-09-24 2024-09-20 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のための拡張プロセス及び薬剤
AU2022354059A1 (en) 2021-09-30 2024-03-28 Abbott Laboratories Methods and systems of diagnosing brain injury
EP4417626A1 (de) 2021-10-14 2024-08-21 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Neuartiges antikörper-zytokin-fusionsprotein, herstellungsverfahren dafür und verwendung davon
CR20240199A (es) 2021-10-14 2024-10-16 Teneobio Inc Proteínas de unión a la mesotelina y usos de las mismas
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
WO2023072958A1 (en) 2021-10-25 2023-05-04 Fabmid Methods for circularizing linear double stranded nucleic acids and the products thereof
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2024544867A (ja) 2021-11-10 2024-12-05 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ８腫瘍浸潤リンパ球を利用する拡張治療の方法
US12290565B2 (en) 2021-11-17 2025-05-06 Altrubio Inc. Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers
AR127728A1 (es) 2021-11-19 2024-02-21 Pieris Pharmaceuticals Gmbh Nueva proteína de fusión específica para ox40 y pd-l1
US20250011405A1 (en) 2021-11-19 2025-01-09 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
EP4445911A1 (de) 2021-12-06 2024-10-16 Beijing SoloBio Genetechnology Co., Ltd. Bispezifischer antikörper mit spezifischer bindung an klebsiella pneumoniae-o2- und o1-antigene sowie zusammensetzung
EP4444343A1 (de) 2021-12-08 2024-10-16 Incyte Corporation Antimutante calreticulin (calr)-antikörper und verwendungen davon
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
US20250051440A1 (en) 2021-12-14 2025-02-13 Institut National de la Santé et de la Recherche Médicale Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
US11767366B1 (en) 2021-12-15 2023-09-26 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2023118497A1 (en) 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
WO2023122796A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Parallel antibody engineering compositions and methods
WO2023144235A1 (en) 2022-01-27 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
JP2025504908A (ja) 2022-01-28 2025-02-19 アイオバンス バイオセラピューティクス，インコーポレイテッド サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
WO2023148707A1 (en) 2022-02-07 2023-08-10 Yeda Research And Development Co. Ltd. Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies
CN118765204A (zh) 2022-02-23 2024-10-11 艾利妥 抗trem2抗体的使用方法
GB202202569D0 (en) 2022-02-24 2022-04-13 Amlo Biosciences Ltd Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
KR20240155347A (ko) 2022-03-09 2024-10-28 알데란 바이오테크놀로지 항-cd160 막관통 동형 항체
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
MX2024011181A (es) 2022-04-01 2024-09-18 Genentech Inc Derivados de hidroxipropilmetilcelulosa para estabilizar polipeptidos.
JP2025512313A (ja) 2022-04-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
US20250231193A1 (en) 2022-04-11 2025-07-17 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
JP2025516551A (ja) 2022-05-10 2025-05-30 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｉｌ－１５ｒアゴニストと併用した腫瘍浸潤リンパ球療法によるがん患者の治療
EP4527857A1 (de) 2022-05-17 2025-03-26 Suzhou Transcenta Therapeutics Co., Ltd. Bifunktionelles protein, seine herstellung und verwendung
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
TW202412744A (zh) 2022-06-07 2024-04-01 瑞士商意梭凱普公司 包括應用在食道黏膜之藥劑的藥物遞送系統及其應用
AU2023284422A1 (en) 2022-06-07 2024-12-19 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
WO2023237661A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
KR20250024900A (ko) 2022-06-17 2025-02-20 제넨테크, 인크. 친화성 크로마토그래피 정제 단계의 수율을 향상시키기 위한 코스모트로프의 용도
EP4543473A1 (de) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau-bindende verbindungen
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
EP4547252A1 (de) 2022-06-30 2025-05-07 ICM (Institut du Cerveau et de la Moelle Épinière) Inhibitoren des vaskulären endothelialen wachstumsfaktorrezeptor-1 (vegfr-1) zur förderung der myelinisierung und neuroprotektion
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
EP4551219A1 (de) 2022-07-06 2025-05-14 Institut National de la Santé et de la Recherche Médicale Verfahren zur behandlung von proliferativer glomerulonephritis
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
WO2024013234A1 (en) 2022-07-13 2024-01-18 Institut National de la Santé et de la Recherche Médicale Methods for diagnosis, prognosis, stratification and treating of myocarditis
EP4554961A2 (de) 2022-07-14 2025-05-21 The Broad Institute, Inc. Aav-kapside zur zns-weiten genverabreichung durch interaktionen mit dem transferrin-rezeptor
TW202417503A (zh) 2022-07-19 2024-05-01 美商舒泰神（加州）生物科技有限公司 特異性識別ｂ和ｔ淋巴細胞衰減器（ｂｔｌａ）的抗體及其應用
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
CN119895039A (zh) 2022-07-25 2025-04-25 因特尔乌斯生物治疗公司 突变多肽、包含所述突变多肽的组合物及其用途
EP4311557A1 (de) 2022-07-26 2024-01-31 Oncomatryx Biopharma, S.L. Auf fap abzielende antikörper-arzneimittelkonjugate
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
EP4565683A1 (de) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimäre kostimulatorische rezeptoren, chemokinrezeptoren und deren verwendung in zellulären immuntherapien
WO2024028433A1 (en) 2022-08-04 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
IL319060A (en) 2022-08-18 2025-04-01 Immunocore Ltd MAGE A4-specific T-cell receptor fusion proteins
EP4584299A2 (de) 2022-09-07 2025-07-16 Quantitative Biosciences, Inc. Fentanyl-spezifische einzel-antikörper mit variabler domäne und verwendung in einem kontinuierlichen agglutinationstest
AU2023343487A1 (en) 2022-09-15 2025-03-20 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
CN120188044A (zh) 2022-09-15 2025-06-20 雅培实验室 用于区分轻度创伤性脑损伤与超轻度创伤性脑损伤的生物标志物和方法
IL319121A (en) 2022-09-15 2025-04-01 Voyager Therapeutics Inc Tau-binding compounds
KR20250069943A (ko) 2022-09-21 2025-05-20 씨젠 인크. Cd228과 결합하는 항체
EP4590695A1 (de) 2022-09-21 2025-07-30 Seagen Inc. Neues cd137 und cd228 spezifisches fusionsprotein
CN119998321A (zh) 2022-09-27 2025-05-13 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
CN119998459A (zh) 2022-09-30 2025-05-13 富士胶片株式会社 产生目标物质的细胞的筛选方法、核酸的制造方法及目标物质的制造方法
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
WO2024083021A1 (zh) 2022-10-20 2024-04-25 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
AU2023369998A1 (en) 2022-10-24 2025-01-23 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists
IL320469A (en) 2022-10-28 2025-06-01 Chinook Therapeutics Inc Treatment of IGA nephropathy with an endothelin receptor antagonist and an APRIL-binding antibody
TW202421194A (zh) 2022-11-03 2024-06-01 美商英塞特公司 包含抗ｇｉｔｒ抗體之用於治療癌症的組合療法
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024102734A1 (en) 2022-11-08 2024-05-16 Genentech, Inc. Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100663A1 (en) 2022-11-10 2024-05-16 Famewave Ltd. Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
WO2024108178A1 (en) 2022-11-18 2024-05-23 Genentech, Inc. Signal amplification and multiplexing using mass tags for ia-lc-ms/ms based assays
AU2023385185A1 (en) 2022-11-21 2025-05-08 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
US12110344B2 (en) 2022-11-21 2024-10-08 Dianthus Therapeutics Opco, Inc. Antibodies that bind to cis and uses thereof
CN120225666A (zh) 2022-11-21 2025-06-27 艾欧凡斯生物治疗公司 用于评估基因编辑的t细胞的增殖效力的方法
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
EP4382120A1 (de) 2022-12-05 2024-06-12 Institut Regional du Cancer de Montpellier Monoklonale anti-slc1a4-antikörper und verwendungen davon
WO2024133573A1 (en) 2022-12-20 2024-06-27 Nextera As Antigen binding proteins
GB202219294D0 (en) 2022-12-20 2023-02-01 Nextera As Antigen binding proteins
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
AU2023412611A1 (en) 2022-12-23 2025-07-10 Chimagen Biosciences, Ltd Novel anti-gprc5d antibody
WO2024131956A1 (zh) 2022-12-23 2024-06-27 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
WO2024141496A1 (en) 2022-12-27 2024-07-04 Merck Patent Gmbh Vhh anti-protac antibodies and complexes
TW202432591A (zh) 2023-01-06 2024-08-16 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024165403A1 (en) 2023-02-06 2024-08-15 Philogen S.P.A. Anti-cea antibodies
WO2024165500A1 (en) 2023-02-06 2024-08-15 Merck Patent Gmbh Vhh-based nkp46 binders
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
WO2024175760A1 (en) 2023-02-24 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
TW202436354A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗cldn6抗體以及其使用方法
AR132063A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
AR132062A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cd3 y métodos de uso
GB202303531D0 (en) 2023-03-10 2023-04-26 Fusion Antibodies Plc Antibodies and uses thereof
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
GB202303784D0 (en) 2023-03-15 2023-04-26 Institute Of Cancer Res Royal Cancer Hospital Cancer treatment
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024209089A1 (en) 2023-04-07 2024-10-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024246224A1 (en) 2023-05-30 2024-12-05 Philikos B.V. Methods and means for the treatment of chronic inflammatory and autoimmune disease
TW202504641A (zh) 2023-06-08 2025-02-01 美商建南德克公司 用於淋巴瘤之診斷及治療方法的巨噬細胞特徵
WO2024251983A1 (en) 2023-06-09 2024-12-12 Merck Patent Gmbh Il-18 mimetics
WO2024258743A1 (en) 2023-06-13 2024-12-19 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
WO2024256583A1 (en) 2023-06-14 2024-12-19 Immutrin Ltd Anti-fibril antibodies
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法
TW202509219A (zh) 2023-07-13 2025-03-01 美商艾歐凡斯生物治療公司 編碼細胞介素之慢病毒載體及其用於製備腫瘤浸潤性淋巴球之用途
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025021928A1 (en) 2023-07-25 2025-01-30 Merck Patent Gmbh Iduronidase-cleavable compounds
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025040797A1 (en) 2023-08-23 2025-02-27 Depth Charge Ltd Interleukin-2 variant proteins that facilitate covalent chemical conjugation and uses thereof
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
TW202513576A (zh) 2023-09-08 2025-04-01 美商建南德克公司 高黏度超濾／滲濾及單程切向流過濾過程
WO2025054500A2 (en) 2023-09-08 2025-03-13 Mlab Biosciences, Inc. Bifunctional proteins and uses thereof
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025096716A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025109043A2 (en) 2023-11-22 2025-05-30 Institut National de la Santé et de la Recherche Médicale Use of neutralizing anti-agr2 antibodies for preventing resistance to chemotherapy
EP4563586A1 (de) 2023-11-28 2025-06-04 Université Paris Cité Neue inhibitoren der lrrk2/pp1-interaktion
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025141153A1 (en) 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
EP4578463A1 (de) 2023-12-29 2025-07-02 Oncomatryx Biopharma, S.L. Gegen endo-180 gerichtete antikörper-wirkstoff-konjugate
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) * 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins

Also Published As

Publication number Publication date
EP1136556A1 (de) 2001-09-26
DK0617706T3 (da) 2001-11-12
DE69232137D1 (de) 2001-11-22
JPH07501451A (ja) 1995-02-16
EP0617706B1 (de) 2001-10-17
DK1136556T3 (da) 2005-10-03
EP0617706A4 (en) 1995-09-27
WO1993011161A1 (en) 1993-06-10
DE69233528T2 (de) 2006-03-16
US20060063715A1 (en) 2006-03-23
CA2122732C (en) 2008-04-08
ATE207080T1 (de) 2001-11-15
AU3178993A (en) 1993-06-28
ATE297465T1 (de) 2005-06-15
CA2122732A1 (en) 1993-06-10
ES2241710T3 (es) 2005-11-01
DE69232137T2 (de) 2002-05-29
EP1136556B1 (de) 2005-06-08
ES2165851T3 (es) 2002-04-01
EP0617706A1 (de) 1994-10-05

Similar Documents

Publication Publication Date Title
DE69233528D1 (de) Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
DE3382190D1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE69020466D1 (de) Collagen-Zubereitungen und Verfahren zur Herstellung davon.
DE69233104D1 (de) Herstellung von Antikörpern
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
DE59100830D1 (de) Verfahren zur Herstellung von 3-Aminomethyl-3,5,5,-trimethyl-cyclohexylamin.
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE59300058D1 (de) Verfahren zur Herstellung von acyliertes aminofunktionelles Organopolysiloxan enthaltenden Emulsionen.
DE69200331D1 (de) Verfahren zur Herstellung von Emulsionen mit tafelförmigen Körnern von hohem Chloridgehalt (III).
DE59400013D1 (de) Verfahren zur Herstellung von Methylchlorsilanen.
DE3485054D1 (de) Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
DE69111104D1 (de) Verfahren zur Herstellung von Alkoxysilane.
DE59100547D1 (de) Verfahren zur Herstellung von linearen Polyamiden.
DE69013482D1 (de) Verfahren zur Herstellung von Organohalosilanen.
DE3883724D1 (de) Verfahren zur Herstellung von Aminen vom Allyltyp.
DE59300777D1 (de) Verfahren zur Herstellung von Perfluorpolyethern.
DE68910771D1 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
DE59105224D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolidonen.
DE69126592D1 (de) Nicht-lineare Peptide, die hydropatisch komplementär zu bekannten Aminosäuresequenzen sind, Verfahren zur Herstellung und Verwendung davon
DE69101329D1 (de) Verfahren zur Herstellung von D-(-)-4-Hydroxyphenylglyzin aus D.L.-4-Hydroxyphenylglyzin.
DE59201146D1 (de) Verfahren zur Herstellung von Methylchlorsilanen.
DE69013621D1 (de) Verfahren zur Herstellung von tertiärem Amino-Alkohol.
DE69105387D1 (de) Verfahren zur Herstellung von Di-tert.-butyl-dicarbonat.
DE69010526D1 (de) Verfahren zur Herstellung von L-Alanin.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition